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Abstract
Common genetic variants at the SLC39A8 locus are genome-wide significantly associated with a variety of
traits in human, and SLC39A8 loss-of-function results in developmental defects in multiple organs of both
human and mice. SLC39A8 encodes ZIP8, a metal ion transporter best known for transporting manganese
(Mn) and zinc (Zn), two essential nutrients required for general metabolism. The goal of my dissertation is to
explore the mechanism in which SLC39A8 mediates metal ion transport in vivo and to test the hypothesis
that SLC39A8 pleiotropically influences complex traits by regulating metal ion transport. I took advantage of
novel Slc398a8 mouse models, cell lines, and samples from human carriers of an SLC39A8 variant. I
discovered that hepatic Zip8 reclaims Mn from biliary excretion to maintain whole-body Mn homeostasis,
and that hepatic Zip8 is a quantitative regulator of whole-body Mn. Slc39a8 deletion in mice leads to protein
N-glycosylation defects indicative of decreased activity of a Mn-dependent enzyme, β-1,
4-galactosyltransferase, while homozygosity of a SLC39A8 loss-of-function variant is associated with
hypogalactosylation, suggesting that protein N-glycosylation may be related to the association of SLC39A8
with complex traits in GWAS. Slc39a8 acts through Mn to quantitatively modulate the activity of arginase,
another Mn-dependent enzyme that influences blood pressure via nitric oxide (NO). Slc39a8 deletion in
mice results in increased NO production, decreased blood pressure, and protection against high-salt-induced
hypertension, while homozygosity of the SLC39A8 loss-of-function variant in human is associated with
increased NO, providing a plausible explanation for the association of SLC39A8 with blood pressure. Slc39a8
deletion in combination with a Zn deficient diet decrease HDL-C in the blood, suggesting Zn may be
involved in the association of SLC39A8 with HDL-C. During embryonic development, Slc39a8 deletion in
mice recapitulates hallmarks of left ventricular noncompaction, a rare cardiomyopathy in human.
Mechanistically, Slc39a8 deletion decreases cellular Zn uptake, which leads to reduced metal-regulatory
transcription factor 1 transcriptional activity, decreased Adamts metalloproteinase transcription, and impaired
extracellular matrix degradation that has been implicated in noncompaction. Thus my dissertation reveals the
mechanism in which Slc39a8 mediates Mn transport in vivo and demonstrates that Slc39a8 acts through Mn
and Zn to modulate the activity of Mn and Zn-dependent enzymes and transcription factors, which in turn
pleiotropically influence complex traits especially blood pressure and heart ventricle development.
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ABSTRACT 
 
SLC39A8/ZIP8 INFLUENCES COMPLEX TRAITS BY REGULATING METAL ION 
METABOLISM 
Wen Lin 
Daniel J. Rader 
Common genetic variants at the SLC39A8 locus are genome-wide significantly 
associated with a variety of traits in human, and SLC39A8 loss-of-function results in 
developmental defects in multiple organs of both human and mice. SLC39A8 encodes 
ZIP8, a metal ion transporter best known for transporting manganese (Mn) and zinc (Zn), 
two essential nutrients required for general metabolism. The goal of my dissertation is to 
explore the mechanism in which SLC39A8 mediates metal ion transport in vivo and to 
test the hypothesis that SLC39A8 pleiotropically influences complex traits by regulating 
metal ion transport. I took advantage of novel Slc398a8 mouse models, cell lines, and 
samples from human carriers of an SLC39A8 variant. I discovered that hepatic Zip8 
reclaims Mn from biliary excretion to maintain whole-body Mn homeostasis, and that 
hepatic Zip8 is a quantitative regulator of whole-body Mn. Slc39a8 deletion in mice leads 
to protein N-glycosylation defects indicative of decreased activity of a Mn-dependent 
enzyme, β-1, 4-galactosyltransferase, while homozygosity of a SLC39A8 loss-of-function 
variant is associated with hypogalactosylation, suggesting that protein N-glycosylation 
may be related to the association of SLC39A8 with complex traits in GWAS. Slc39a8 
acts through Mn to quantitatively modulate the activity of arginase, another Mn-
dependent enzyme that influences blood pressure via nitric oxide (NO). Slc39a8 deletion 
in mice results in increased NO production, decreased blood pressure, and protection 
against high-salt-induced hypertension, while homozygosity of the SLC39A8 loss-of-
v 
function variant in human is associated with increased NO, providing a plausible 
explanation for the association of SLC39A8 with blood pressure. Slc39a8 deletion in 
combination with a Zn deficient diet decrease HDL-C in the blood, suggesting Zn may be 
involved in the association of SLC39A8 with HDL-C. During embryonic development, 
Slc39a8 deletion in mice recapitulates hallmarks of left ventricular noncompaction, a rare 
cardiomyopathy in human. Mechanistically, Slc39a8 deletion decreases cellular Zn 
uptake, which leads to reduced metal-regulatory transcription factor 1 transcriptional 
activity, decreased Adamts metalloproteinase transcription, and impaired extracellular 
matrix degradation that has been implicated in noncompaction. Thus my dissertation 
reveals the mechanism in which Slc39a8 mediates Mn transport in vivo and 
demonstrates that Slc39a8 acts through Mn and Zn to modulate the activity of Mn and 
Zn-dependent enzymes and transcription factors, which in turn pleiotropically influence 
complex traits especially blood pressure and heart ventricle development.  
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CHAPTER 1: INTRODUCTION 
 
GWAS principles 
A major goal of human genetics studies is to identify risk factors for rare Mendelian 
disorders and common complex diseases. Rare Mendelian disorders are largely caused 
by rare genetic variants, or mutations, that drastically alter the function of a protein. In 
contrast, the “common disease, common variant” hypothesis suggests that common 
complex diseases are usually attributable to a number of common genetic variations, or 
single nucleotide polymorphisms  (SNPs), that are present in more than 1%–5% of the 
population and have minimal effects on the expression of a gene, or function of a protein 
(1). Classically, mutations for rare Mendelian disorders have been identified using 
linkage analysis, which examines how genetic variants segregate with the disease 
across multiple families (2, 3), and more recently, whole genome sequencing and whole 
exon sequencing filtering approaches have gained increasing use (4, 5). However, SNPs 
contributing to common complex diseases have small effect sizes and do not exhibit 
clear pattern of inheritance within families, preventing identification of them using the 
kinship-based approaches cost-effectively (6).  
 
After the publication of the draft human genome sequence in 2001 (7) and the 
essentially finished version in 2003 (8), the International HapMap Project was launched 
to catalog the SNPs across the human genome, to determine their frequencies, and to 
characterize the patterns in which they correlate. Starting with roughly 3 millions of SNPs 
in 4 populations including European descent populations, Yoruba population of African 
origin, Han Chinese individuals from Beijing, and Japanese individuals from Tokyo, the 
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International HapMap Project has since extended to 11 populations (9, 10). According to 
the currently available data from the International HapMap Project, roughly 10 million 
SNPs with minor allele frequency greater than 1% exist in the human population (11). 
Nearby variants on the same chromosome can be non-randomly associated (linkage 
disequilibrium), and variants at multiple linked loci on a chromosome can be transmitted 
together (haplotype) (12). Combining the effects of linkage disequilibrium and haplotype, 
it is estimated that a subset of 500,000 to one million SNPs across the genome is 
sufficient to capture more than 80% of commonly occurring SNPs (minor allele frequency 
greater than 5%) in European descent (13).  
 
The International HapMap Project has enabled genome-wide association studies 
(GWAS), a new paradigm of research that interrogates the human genome in a 
comprehensive manner. It scans the genome of unrelated individuals and appropriately 
matched controls or parent-affected child trios to identify SNPs that are associated with a 
trait of a disease state. With the advances of chip-based microarray technology for 
assaying one million or more SNPs (14), GWAS has been widely applied and has 
identified numerous disease-associated common SNPs and genes, providing new 
insights into the etiology of common complex diseases and new therapeutic targets for 
the diseases (15). In addition, by increasing sample size, rare and low-frequency SNPs 
with moderate-to-large effects have also been uncovered using the GWAS approach 
(16). In addition, whole-genome and whole-exome sequencing are being adapted to 
identify rare genetic variants that contribute to the heritability of complex common 
diseases (4, 17).  
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Hypertension 
Hypertension is a risk factor that plays a major etiologic role in the development of CVD, 
cerebrovascular disease and renal failure (18). Multiple clinical trials have demonstrated 
that antihypertensive therapies reduce the risk of CVD and cerebrovascular disease 
outcomes, including stroke (by 35-40%), myocardial infarction (by 15-20%), heart failure 
(by up to 64%), and death from any cause (19-21). Observational studies have shown a 
progressive decrease in vascular (and overall) mortality as blood pressure decreases to 
115/75 mmHg (22). Recently, it was found that intensive blood pressure control (systolic 
blood pressure<120 mm Hg) resulted in lower rates of fatal and nonfatal major 
cardiovascular events and death from any cause compared with standard blood 
pressure control (systolic blood pressure<140 mm Hg) (23).  
 
Blood pressure regulation is a complicated process involving different biological systems 
and a number of feedback systems, including the nervous system, hormones (e.g. 
renin–angiotensin system), body fluid control and regulators within the vessels (24). 
Major classes of antihypertensive therapies include: diuretics, which promote the 
excretion of sodium and extra fluid out of the body; β-blockers, which block the effect of 
adrenaline and noradrenaline on the heart and peripheral vasculature decreasing heart 
rate and the force in which blood is pumped throughout the body; calcium channel 
inhibitors, which inhibit the flow of calcium into smooth muscle in blood vessel walls and 
the heart muscle to inhibit muscle contraction; and renin-angiotensin system inhibitors 
(including angiotensin-converting enzyme inhibitors and angiotensin receptor blockers), 
which reduce the production or effect of the potent vasoconstrictor Angiotensin II (25).  
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Monotherapy is effective in achieving targeted blood pressure in only about 50 percent of 
patients with hypertension (26), and combination therapy is often required to achieve 
adequate blood pressure control (27). Developing novel antihypertensive therapies will 
facilitate achieving standard blood pressure control and even intensive blood pressure 
control that has been shown to have further health benefits.  
 
Nitric oxide (NO) is a key endothelial-derived vasodilator	  produced when nitric oxide 
synthase (NOS) converts L-arginine to L-citrulline (28). The primary mechanism of action 
of NO in lowering blood pressure is the activation of soluble guanylate cyclase (sGC) in 
the subjacent smooth muscle of the vasculature. sGC converts guanosine triphosphate 
(GTP) to cyclic guanosine monophosphate (cGMP), which activates cGMP-dependent 
protein kinase (PKG) and results in smooth muscle relaxation (29). In addition to direct 
vasorelaxation effect, there is evidence that NO may act in the central nervous system to 
reduce vascular sympathetic tone (30). It has been shown that NO influences the 
vascular tone of coronary and brachial conduit vessels, large central arteries and 
peripheral vasculature (31), and that reduced NO bioavailability increases blood 
pressure (32).	  Inhaled NO has been used to treat conditions related to pulmonary 
hypertension (33), and intravenous nitrovasodilators, which release NO upon activation, 
have been used to treat angina pectoris (Nitroglycerin) and hypertensive crisis (Sodium 
nitroprusside) (34). The vasodilatory effect of inhaled NO is limited largely to the lung 
(35), and intravenous nitrovasodilators can produce tolerance (Nitroglycerin) or severe 
systemic arterial hypotension (Sodium nitroprusside) (36).  
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Blood pressure is a common complex trait, and the heritability of blood pressure is 
estimated to be 30-50% (37). Early monogenic studies have revealed 12 genes in the 
renal sodium handling and steroid hormone metabolism pathways that are involved in 
the development of monogenic hypertension (38, 39). In terms of essential hypertension, 
which has no evident cause and accounts for 95 % cases of hypertension (40), 
candidate gene and genome-wide linkage studies have had limited success and only the 
Angiotensinogen locus has been identified (39). In contrast, genome-wide association 
studies have reported more than 60 novel loci associated with blood pressure or 
hypertension, and some of the results have been verified across different ethnicities. 
Identifying the causal genes in these loci and elucidating the mechanism will advance 
our understanding of blood pressure regulation and highlight potential targets for the 
development of antihypertensive therapies.  
 
The SLC39A8 locus 
One intriguing phenomenon emerging from GWAS is pleiotropic associations of an 
individual SNP with multiple traits (41), for which there are multiple examples among loci 
associated with metabolic syndrome. Metabolic syndrome is defined by a constellation of 
interconnected physiological, biochemical, clinical, and metabolic factors that directly 
increase the risk of cardiovascular disease (CVD), type 2 diabetes mellitus (T2DM), and 
all cause mortality (42, 43). Factors that contribute to the pathogenesis of metabolic 
syndrome include hypertension, insulin resistance, hyperglycemia, visceral adiposity, 
atherogenic dyslipidemia, endothelial dysfunction, genetic susceptibility, 
hypercoagulable state, and chronic stress (44). Genes influencing insulin levels exhibit 
pleiotropic associations with lipoprotein and obesity measures (45), and obesity-
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susceptibility loci have pleiotropic effects on other metabolic traits (46). These cross-
phenotype associations suggest that distinct complex traits and diseases, such as 
different components of the metabolic syndrome, may have common genetic 
components and pathways (47). Characterizing these pleiotropic associations, including 
the causal SNPs, causal genes, and the underlying molecular mechanisms, will further 
our understanding of the biology of complex traits and will have clinical implications for 
drug discovery.  
 
Genetic variants at the 4q24 locus including the SLC39A8 gene are genome-wide 
significantly associated with multiple metabolic traits, including blood pressure (48, 49), 
HDL-C (50, 51), and BMI (52). The associations with blood pressure and HDL-C are 
independent of BMI (46). In addition, the locus is associated with whole blood Mn (53), 
schizophrenia (54, 55), and Crohnʼs Disease (56). The lead SNP consistently associated 
with these traits is a coding variant rs13107325 (Ala391Thr), which has an 8% minor 
allele frequency in people with European ancestry and is monomorphic in African and 
Asian populations (57, 58). The minor allele is associated with lower blood pressure, 
lower HDL-C, higher BMI, lower whole blood Mn, and increased risk for schizophrenia 
and Crohnʼs disease. Despite the fact that the preponderance of the trait associations is 
intuitively undesirable (other than lower blood pressure), the minor allele has undergone 
an expansion in Europeans, apparently driven by recent positive selection (58).  
 
Rs13107325 (Ala391Thr) has been shown in silico and in vitro to produce a protein that 
has reduced function (59, 60). In addition, it is an expression quantitative trait locus 
(eQTL) for SLC39A8 specifically in liver, with the minor allele associated with decreased 
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SLC39A8 mRNA levels [the eQTL signal was not detected in brain, adipose, whole 
blood, or lymphocytes (50, 52), and an allelic expression imbalance assay of 
rs13107325 in human umbilical vein endothelial cells (HUVECs) showed no difference in 
the level of SLC39A8 mRNA with the major and minor allele (59)]. These data suggest 
that rs13107325 is likely the causal SNP and SLC39A8 is likely the causal gene 
underlying the association of the SLC39A8 genomic locus with pleiotropic traits.    
 
The SLC39A8 gene and ZIP8 protein 
The human and mouse genome have 14 Solute Carrier 39 (SLC39) genes, and each of 
the 14 genes in mouse has an ortholog in human that is highly conserved. SLC39A1-14 
encode ZRT, IRT-like proteins 1-14 (ZIP1-14) that belong to the broad ZIP family of 
divalent metal ion transporters (61). Where characterized, ZIP proteins transport divalent 
metal ions, including Zn, Fe, and Mn, from the cell exterior or lumen of intracellular 
organelles into the cytoplasm (62). The crystal structure of ZIP proteins and biochemical 
mechanism in which they interact with and transport substrates remain unknown.  
 
SLC39A8 was first discovered as BIGM103 in a cDNA screening to identify novel genes 
induced by innate immune activation. The protein encoded by SLC39A8/BIGM103 
showed homology to the ZIP family of divalent metal ion transporters and was later 
renamed ZIP8 (63). SLC39A8/ZIP8 is closely related to SLC39A14/ZIP14 and distantly 
related to other family members in the SLC39 phylogenetic tree (64). ZIP8 is a 
membrane protein with 7 predicted transmembrane domains. Ala391Thr is located in the 
conserved intracellular loop between the 5th and 6th transmembrane (65). Metal ion 
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transport by ZIP8 is dependent on the presence of bicarbonate, and the maximal activity 
is attained under 37°C and at neutral pH (66). 
 
ZIP8 is widely expressed across tissues in both human and mouse. It is highly 
expressed in the pancreas, lung, placenta, and liver of human and lung, testis, kidney, 
and placenta of mice (63, 64). It has been detected in lung epithelial cells (67), renal 
proximal tubule cells, endothelial cells of vasculature (68),	  and	  urothelium (69). It is 
expressed mostly in the plasma membrane, though lysosome (70) and mitochondria (71) 
localizations have also been reported, where it may function to maintain metal ion 
homeostasis in the organelles. It is worth noting that membrane ZIP8 tend to localize on 
the apical surface. It has been detected on the apical surface of human lung epithelial 
cells (71) and canine kidney epithelial cells (72), and there is evidence that it is localized 
on the apical surface of the proximal tubule epithelial cells (73).   
 
SLC39A8 is expressed as early as the gastrula stage in visceral endoderm at embryonic 
day E7.5 of mice (74), and it is highly expressed in the placenta of both human and 
mice. However, the role it plays during development and overall physiology is unknown. 
A Slc39a8 hypomorphic allele was reported in 2011, and it contains a neomycin-
resistance (neo) mini-cassette in intron 3 and loxP sites in introns 3 and 6 of the Slc39a8 
gene. Mice homozygous for this allele exhibited dramatically decreased Slc39a8 mRNA 
and ZIP8 protein in embryo, fetus, placenta, yolk sac, and several tissues of neonates 
(75). Phenotypically, the mice developed stunted-growth, multiple-organ hypoplasia, 
anemia, and perinatal death of unknown cause, but accompanied by diminished Zn and 
Fe levels in several tissues (76). In 2015, mutations of the SLC39A8 gene were 
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identified in human. These patients were either homozygous or compound heterozygous 
for SLC39A8 mutations. Phenotypically, they displayed intellectual disability with 
cerebellar atrophy syndrome, neurological and skeletal abnormalities characteristic of 
type II congenital disorders of glycosylation (CDG), and developmental delay, dystonia, 
seizures and failure to thrive characteristic of Leigh-like mitochondrial disease. 
Biochemically, they exhibited protein N-glycosylation defects, especially 
hypogalactosylation, and dysregulation of respiratory chain enzyme activity. Importantly, 
all of these patients had variably low Mn levels in the whole blood or plasma (77-79). 
These findings in mice and human suggest that SLC39A8/ZIP8 loss-of-function has 
pleiotropic effects mediated by the role of SLC39A8 in metal ion transport. 
 
In adults, multiple studies have demonstrated that SLC39A8 expression is strongly 
induced by pro-inflammatory stimuli (67, 71, 80, 81). ZIP8 level was found to be elevated 
in the lung epithelia and macrophages of mice undergoing bacteria infection and sepsis, 
and it was shown in vitro that NF-κB-mediated ZIP8 activation negatively regulated pro-
inflammatory responses through Zn-mediated inhibition of NF-κB activity (80). ZIP8 was 
also found to be elevated in the lung epithelia of chronic smokers, and it was shown in 
vitro that NF-κB-mediated ZIP8 activation enhanced cadmium-mediated toxicity to lung 
epithelia (67). More recently, it was found that ZIP8 was up-regulated in osteoarthritic 
cartilage in humans and mice, and that ectopic ZIP8 expression in vivo resulted in 
cartilage destruction by promoting cellular Zn uptake, which acted through the metal-
regulatory transcription factor 1 (MTF1) to increase the expression of extracellular 
degrading enzymes (81). These observations demonstrate that in adult stage, 
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SLC39A8/ZIP8 is involved in diverse physiological and pathological processes by 
promoting cellular metal ion uptake. 
 
The substrates of ZIP8 
In vitro, mouse Zip8 has been shown to promote cellular uptake of Zn, Fe, Mn, and Cd in 
mammalian cell lines and oocytes (63, 67, 72, 73, 82). It has a Km of 0.26 ± 0.09	  µM for 
Zn and 0.48 ± 0.08 µM for Cd when over-expressed in oocytes (66), and a Km of 0.62 
µM for Cd and 2.2 µM for Mn when over-expressed in mouse embryonic fibroblasts (72). 
Knocking down ZIP8 significantly reduced Mn and Cd uptake from the apical membrane 
of mouse kidney proximal tubule cells (73). Furthermore, rs13107325 (Ala391Thr) has 
been shown to impair Cd (59) and Zn (60) uptake by ZIP8 in HEK293T cells.  
 
In vivo, Slc39a8 hypomorph mouse newborns exhibited stunted growth, multiple-organ 
hypoplasia, anemia and perinatal death accompanied by diminished tissue Zn and Fe 
(76). Patients carrying SLC39A8 mutations developed type II congenital disorders of 
glycosylation (CDG-II) accompanied by severe Mn deficiency and occasional Zn 
deficiency (77-79). Mice with lower Slc39a8 expression in the testicular vascular 
endothelium were resistant, while mice with high Slc39a8 expression in the testicular 
vascular endothelium were sensitive to Cd-induced testicular necrosis (83). These 
observations, together with the association of SLC39A8 with whole blood Mn and 
pleotropic traits in GWAS, suggest that Mn, Zn and Cd are all possible physiological 
substrates of ZIP8 and that they may be underlying the pleotropic roles of ZIP8 in 
physiology and pathology.  
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Mn: essentiality and transport machinery 
Nutrients required for specific metabolic functions are referred to as “type I nutrients”, 
and those required for general metabolic functions are referred to as “type II nutrients” 
(84). Mn is a type II nutrient that plays essential roles in the metabolism of amino acid, 
lipid, and carbohydrate, and is crucial for multiple physiological processes including 
reproduction, development, digestion, immune function, blood clotting, and antioxidant 
defenses (85).  
 
An important reason underlying the essentiality of Mn is that it serves as a cofactor for 
numerous enzymes. These Mn-dependent enzymes include Mn-activated enzymes and 
Mn metalloenzymes. Mn-activated enzymes typically have tight, rapidly-reversible Mn-
specific sites involved with either catalytic or regulatory function. The rapidly-reversible 
binding of Mn allows the enzymatic activity to be modulated by fluctuations of Mn in the 
cellular compartment where the enzymes are resided. On the other hand, Mn 
metalloenzymes bind to Mn so tightly that they co-isolate with the ion (86). Mn-activated 
enzymes encompass all six major enzyme families, including transferases, 
oxidoreductases, hydrolases, lyases, isomerases, and ligases, and include a remarkable 
number of enzymes of major metabolic or regulatory importance (86). One relatively 
well-established family of Mn-activated enzymes is glycosyltransferase, which plays 
important roles in the synthesis of glycoprotein and proteoglycan. Decreased 
glycosyltransferase activity due to Mn deficiency in vivo has been shown to impair 
mucopolysaccharide synthesis (87-89) and protein N-glycosylation (77, 79, 90), resulting 
in profound skeletal and neurological defects. In comparison to Mn-activated enzymes, 
Mn metalloenzymes are far less common. They include arginase (91), pyruvate 
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carboxylase (92), Mn-superoxide dismutase (MnSOD) (93), and glutamine synthase 
(94). Pyruvate carboxylase controls fuel partitioning toward gluconeogenesis, 
lipogenesis, and insulin secretion (95), MnSOD protects the mitochondria against 
oxidative stress by catalyzing the dismutation of superoxide (93), and arginase (96) and 
glutamine synthetase (97) play essential roles in nitrogen metabolism. 
 
Mn is present in all human tissues at concentrations ranging from 0.3 to 2.9 µg/g wet 
tissue, and the tissues particularly rich in Mn are the liver, kidney, pancreas, bone, and 
parts of the brain including basal ganglia and cerebellum (85). The major source of Mn 
for human is dietary intake, and daily dietary requirement of Mn is 2.3 mg for men and 
1.8 mg for women (98). Mn ubiquitously exists in a variety of food, especially whole 
grains, legumes, rice and nuts. The variety of Mn-containing dietary sources has allowed 
human to easily obtain adequate Mn (98). 
 
In human, nutritional Mn deficiency has not been described under normal situations. 
However, mild to moderate nutritional Mn deficiency created experimentally have 
resulted in lower cholesterol, dermatitis, and altered mood and pain perception (99, 100). 
Furthermore, severe Mn deficiency caused by genetic mutations has been shown to 
impair protein N-glycosylation and result in congenital disorders of glycosylation 
characterized by a series of neurological and skeletal defects (79, 101). In animals, Mn 
deficiency during early development have been shown to impair proteoglycan synthesis 
which leads to irreversible bone abnormalities and ataxia (88), while Mn deficiency 
occurred after the developmental stage has been found to impair insulin production, 
lipoprotein metabolism, oxidant defense system, and growth factor metabolism (102).  
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In contrast to Mn deficiency, an extensive literature has detailed the clinical syndrome 
and pathophysiology of Mn toxicity in human, especially neurotoxicity resulted from Mn 
over-exposure and accumulation in the brain. The most common Mn-induced 
neurotoxicity is manganism, or manganese-induced Parkinsonism, characterized by 
extrapyramidal dysfunctions such as bradykinesia and rigidity. It was first described in 
1837 in five Mn ore crushers that exhibited tremor in the extremities, gait disturbance, 
and whispering (103).	  More cases have been reported over the years	  (104, 105). The 
symptoms of manganism overlap considerably, though not completely, with Parkinsonʼs 
disease, suggesting a potential link between these two diseases. Mn-induced 
neurotoxicity has also been reported in neonates receiving total parenteral nutrition(106) 
and patients carrying a genetic mutation in two metal ion transporters, SLC30A10 (107) 
and SLC39A14 (108). In addition, there is increasing evidence that Mn may contribute to 
the pathogenesis of neurological disorders of liver disease patients (109-111), potentially 
due to insufficient Mn disposal by the liver.  
 
Mn homeostasis is tightly controlled by absorption from small intestine (112) and 
excretion from biliary (113, 114). Only 1-5% of ingested Mn is absorbed from small 
intestine (115), and about 90% of absorbed Mn is excreted into the bile. A significant 
fraction of biliarily excreted Mn undergoes enterohepatic circulation (116). Increased 
dietary exposure to Mn leads to decreased gastrointestinal absorption and increased 
biliary excretion, while decreased dietary exposure to Mn induces opposite homeostatic 
adaptations (117, 118). Gender and age are two important biological variables in the 
regulation of Mn homeostasis. For instance, it has been shown in human that female 
subjects absorb more Mn than male, while male subjects retain more Mn than female 
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(119). In agreement with this, male rats were found to retain more Mn than did female 
rats by decreasing the rate of Mn excretion (120). In terms of age, it has been found that 
younger age is significantly associated with high blood Mn in human (121), and that 
younger rats absorb more Mn and excrete Mn more quickly than do older rats (120).  
 
Mn is taken up by hepatocytes as macroglobulin or albumin-bound Mn2+ and excreted 
into the bile as bilirubin-bound Mn2+ (122), while Mn that escapes first-pass liver 
elimination enters circulation primarily as Mn3+ bound to transferrin (123, 124). In 
addition to ZIP8, there is evidence that divalent metal transporter 1 (DMT1) (encoded by 
SLC11A2), SLC30A10, and ZIP14 (encoded by SLC39A14) are involved in Mn2+ 
transport in vivo. For instance, the DMT1-deficient Belgrade rats exhibited decreased 
Mn2+ uptake in the kidneys, brain and femurs (125), though DMT1 was found to be 
dispensable for Mn2+ uptake in the liver (125) and small intestine (126). Patients 
carrying SLC30A10 mutations developed hypermanganesemia and Mn-induced 
Parkinsonism (107). Since SLC30A10 is detectable in the liver, the hypermanganesemia 
may be a result of impaired Mn excretion. Patients carrying SLC39A14 mutations also 
developed excessive accumulation of Mn and Mn-induced Parkinsonism. ZIP14 has 
been localized to the basolateral surface of hepatocytes where nutrients are absorbed 
from the blood (127), therefore the excessive accumulation of Mn may be a result of Mn 
bypassing hepatic uptake and biliary excretion.  
 
Zn: essentiality and transport machinery 
Zn is a type II nutrient that plays an essential role in general metabolism. It catalyzes 
reactions mediated by Zn metalloenzymes and maintains the structure of Zn finger 
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proteins (84). It is estimated that Zn-binding proteins make up over 10% of the human 
proteome (128). Zn metalloenzymes represent all six major classes of enzymes, i.e., 
oxidoreductases, transferases, hydrolases, lyases, isomerases, and ligases. The 
catalytic Zn ion is coordinated by amino acids and water molecules, and participates 
directly in the enzyme catalysis. Removal of Zn abolishes the enzymatic activity of Zn 
metalloenzymes. Some of these enzymes have a co-catalytic Zn ion, which functions to 
modulate the enzymatic activity. Zn finger proteins have extraordinarily diverse functions, 
including DNA recognition, RNA packaging, transcriptional activation, regulation of 
apoptosis, protein folding and assembly, and lipid binding (129). They share Zn finger 
domains that require the binding of Zn for structural stabilization. The classic Zn finger 
motif (C2H2) contains repetitive sequences of C (cysteine) and H (histidine) residues that 
coordinate the binding of Zn ions. This motif constitutes a small protein domain that 
interacts with nucleic acids like the fingers of a hand gripping a rod, hence the name “Zn 
finger.” It is worth noting that Zn finger domains bind to Zn with a spectrum of affinities 
over four logs [Kd = 108 to 1010 M-1, and Kd for metallothionein-1 (MT-1) = 1012 M-1]. The 
more facile sites are potentially influenced by dietary Zn supply (130).  
 
The majority of intracellular Zn is bound, but recent advances have highlighted the 
existence of free or labile Zn. This pool of Zn can act as intracellular signaling molecules 
capable of transducing extracellular stimuli into intracellular signaling events (131). 
Finally, Zn in intracellular organelles has been shown to have unique functions. For 
instance, Zn in pancreatic granules is required for packaging of insulin and Zn in 
neuronal synaptic vesicles is required for secretion of neurotransmitters (132). 
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The World Health Organization (WHO) estimated that the physiological requirement for 
absorbed Zn is 1.97 mg/day for male (64 kg) and 1.54 mg/day for female (55 kg). 
Pregnancy and lactation increase the requirement to 2.27 mg/day and 2.89 mg/day 
respectively (133). Beef and pork are the major source of readily bioavailable Zn in US 
diet, and phytic acid is the main known inhibitor of Zn absorption (134). Therefore, Zn 
deficiency is most prevalent in areas of low animal food and high cereal consumption.  
 
Zn deficiency is associated with broad physiological impacts, but the mechanism is not 
well understood. In addition, a direct link between symptoms of Zn deficiency and the 
function of an individual enzyme has not been identified in complex organisms (84). 
Organs affected by Zn deficiency include epidermal, gastrointestinal, central nervous, 
immune, skeletal, and reproductive organ systems (133). Clinically, severe Zn deficiency 
has been reported in patients of acrodermatitis enteropathica, a rare genetic disease 
caused by SLC39A4 mutations that lead to Zn malabsorption (135), as well as prolonged 
parenteral nutrition with inadequate Zn content (136). Symptoms of Zn deficiency include 
dermatitis, diarrhea, mood changes, anorexia, neurological disturbance, growth 
retardation, alopecia, weight loss, recurrent infections, and mortality. Most of these 
features have been documented also in milder forms of Zn deficiency. 
 
Maternal Zn deficiency has been shown to result in embryo death, intrauterine growth 
retardation, and teratogenesis in all tissues (137-139). In particular, maternal Zn 
deficiency in rats resulted in multiple forms of cardiac abnormalities in the fetus, such as 
thin ventricular wall, ventricular hypoplasia, ventricular septum defect, and irregular 
trabeculation (138, 140). Two genes critical for cardiac development, including a-myosin 
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heavy chain (a-MHC) and cardiac troponin I (cTnI), were down-regulated in these fetus. 
These two genes are downstream targets of the Zn-finger transcription factor GATA4, 
therefore the down-regulation suggest decreased GATA4 transcriptional activity (140).  
 
Zn homeostasis is maintained by adjustments in both intestinal absorption and fecal 
excretion (141). In response to inadequate absorption, excretion is avidly reduced, 
followed by mobilization of Zn from small, vulnerable pool and tissue catabolism if Zn 
homeostasis is not re-established by adaption of excretion (84). In the cellular level, Zn 
homeostasis is tightly controlled by a complex and extensive system, including Zn 
transporters and channels, Zn-sensing molecules such as metallothioneins (MTs), and 
metal-regulatory transcription factor-1 (MTF-1) (142). In addition to ZIP8, there are 13 
ZIP proteins that import Zn into the cytoplasm and 10 ZnT proteins that export Zn from 
the cytoplasm (143). Altering the activity of these transporters has resulted in profound 
physiological impacts. For instance, SLC39A4/ZIP4 mutation in human impairs the 
uptake of dietary zinc into intestinal enterocytes and leads to an autosomal recessive 
metabolic disorder called acrodermatitis enteropathica (144), and SNPs of SLC30A8, an 
islet beta-cell-specific Zn transporter that provides Zn for insulin-crystal formation, is 
associated with the risk for type 2 diabetes in GWAS (145, 146). Zn transporters have 
been shown to participate in signaling transduction by Zn, where extracellular stimuli 
induces the expression of Zn transporters to promote cellular Zn uptake and activate Zn-
sensing transcription factors (147).  
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Cd: toxicity and transport machinery 
Cd is a non-essential toxic heavy metal and an environmental pollutant. It is widely 
distributed in diet, drinking water, air, consumer product and cigarette smoke, with diet 
and cigarette smoking being the main sources of non-occupational exposure (148). Cd 
has an extremely long biological half-life in the body (estimated at 15-30 years) due to an 
extremely slow excretion rate (148). Therefore, the general population is at risk of 
chronic low-dose Cd exposure. 
 
Cd can produce a variety of adverse effects in human and animals, including various 
cancers (148), obstructive lung disorders (149), renal injury (150), osteoporosis (151),	  
atherosclerosis (152) and hypertension (150, 153, 154). On the cellular level, Cd can 
induce oxidative stress (155), interfere with normal actions of essential trace metals 
(156) and cause cell necrosis (157) and apoptosis (158). Identifying proteins that 
mediate Cd metabolism would provide candidate therapeutic targets for Cd-induced 
toxicity. 
 
After absorption, Cd is mostly bound to albumin and taken up by the liver, where it is 
sequestered by metallothionein (MT). The Cd-MT complex is then released into the 
circulation system and deposits in many organs, including liver, kidney, pancreas, and 
testis. In the kidney, the complex is easily filtered through the glomerulus and 
reabsorbed by the proximal tubular epithelial cells via endocytosis (159, 160). Free Cd 
ion also exists and is taken up by transporters. There is evidence that MT binding is 
protective against, rather than causative of, Cd-induced nephrotoxicity (161).  
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Cd enters cells by competing with essential metals, such as Zn and calcium, for 
transporters. Various transporters have shown affinity for Cd in vitro (162), but the only 
Cd transporter established in vivo is SLC39A14 (ZIP14) (163). Compared with wild type 
mice, Slc39a14 null mice displayed decreased accumulation of hepatic Cd but increased 
accumulation of Cd in the kidney and lung after short-term (6 hours to 10 days) oral Cd 
treatment, consistent with a role of Slc39a14 in hepatic metal ion uptake (127). However, 
Cd transporter function in other organs remains elusive.  
 
Multiple lines of evidence suggest that Zip8 may mediate Cd transport in vivo. Slc39a8 
was identified by a genomic analysis to be associated with sensitivity to Cd-induced 
testicular necrosis in mice (83). Cd-sensitive strains had higher Slc39a8 levels in the 
testicular vasculature than the resistant strains, and the resistant strains over-expressing 
Slc39a8 developed testicular necrosis and proximal tubular damage. Interestingly, Zip8 
was detected in the endothelial cells of the testicular vasculature and apical membranes 
of the proximal tubular epithelial cells (68). These observations suggest that Zip8 may 
mediate Cd uptake in the vascular endothelial cells and proximal tubular epithelial cells. 
However, to test the essentiality of Slc39a8 in Cd transport, an Slc39a8 knockout mouse 
model is needed.  
 
The goal of my dissertation 
Given the pleiotropic associations of SLC39A8 with traits in GWAS, the broad 
physiological impacts of SLC39A8 loss-of-function in human and mouse, the essentiality 
of Mn and Zn for metabolism, and the diversity of Mn and Zn-dependent proteins, the 
goal of my dissertation is to reveal the mechanism in which SLC39A8 mediates metal 
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ion transport in vivo and to test the hypothesis that SLC39A8 acts through Mn and Zn to 
modulate the function of Mn and Zn-dependent proteins which in turn pleiotropically 
influence complex traits. 
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CHAPTER 2 
	  
Hepatic SLC39A8/ZIP8 influences protein N-glycosylation by regulating whole-
body manganese homeostasis  
 
Introduction 
Common genetic variants at the SLC39A8 genomic locus are genome-wide significantly 
associated with whole blood manganese (Mn) (53) and a variety of other traits and 
diseases, including blood pressure, high-density lipoprotein cholesterol (HDL-C), body 
mass index (BMI), and schizophrenia (48, 50-52, 54, 55, 164). Importantly, the lead 
variant for all of these traits is a coding variant rs13107325 (Ala391Thr) that has an 8% 
minor allele frequency in people of European ancestry (57), is associated with lower 
whole blood Mn, and has been reported to produce a protein with reduced function (59, 
60). This variant is also an eQTL for SLC39A8 in human liver and is associated with 
lower hepatic SLC39A8 expression (50, 52). However, the mechanisms underlying the 
associations of SLC39A8 with blood Mn and other human physiological traits remain 
unknown. 
 
SLC39A8 encodes a protein known as ZIP8, a divalent metal ion transporter best known 
for its ability to transport zinc (Zn) (63). It has also been shown in vitro to transport Mn 
(72), iron (Fe) (82) and cadmium (Cd) (72), with higher affinity for Mn but not Zn in 
mammalian cells (72). Hypomorphic Slc39a8 mice exhibited diminished tissue Zn and 
Fe, stunted growth, multiple-organ hypoplasia, anemia and perinatal death (76). 
Recently, SLC39A8 mutations were identified in patients of type II congenital disorders 
of glycosylation (CDG), a rapidly growing family of genetic diseases that affects multiple 
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organs and systems(165). SLC39A8-CDG patients developed severe Mn deficiency, 
impaired protein N-glycosylation, and neurological and skeletal defects symptomatic of 
CDG. However, there is virtually nothing known about how ZIP8 regulates metal ion 
metabolism in vivo. 
 
Mn is an essential trace nutrient and a cofactor for numerous enzymes (86). These Mn-
dependent enzymes encompass all six major enzyme families, in addition to several Mn 
metalloenzymes that contain tightly-bound Mn ion(s) (86). A classic example of Mn-
dependent enzyme is β-1, 4-galactosyltransferase, which requires Mn for substrate 
binding and catalytic activity (166). Mn deficiency impairs bone formation, fertility, and 
the metabolism of glucose, lipids and carbohydrates (86, 102). Despite the essentiality of 
Mn, only Dmt1 (125, 167) and SLC30A10 (107, 167) have been established as Mn 
transporters in vivo, and the physiological regulation of Mn metabolism is not well 
understood.  
 
I hypothesized that ZIP8 regulates Mn homeostasis and therefore plays important roles 
in metabolism via regulation of Mn-dependent enzymes. To test this hypothesis, I 
generated Slc39a8 inducible global knockout (Zip8 iKO) and liver-specific knockout (Zip8 
LSKO) mice and also overexpressed SLC39A8 in mouse liver (AAV-ZIP8). This study 
establishes hepatic ZIP8 as a regulator of whole-body Mn homeostasis through 
reclamation of Mn from bile; through this mechanism ZIP8 influences protein N-
glycosylation by regulating the activity of a Mn-dependent enzyme β-1, 4-
galactosyltransferase. 
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Methods 
Animals. Mice harboring Slc39a8 conditional knockout allele, C57BL/6-Slc39a8tm1.1 
mrl, and constitutive knockout allele, C57BL/6-Slc39a8tm1.2 mrl, were provided by 
Merck. Details of the design of the Slc39a8 mice can be found at 
http://www.taconic.com/mouse-model/slc39a8-cko-11296 and 
http://www.taconic.com/mouse-model/slc39a8-ko. Briefly, Slc39a8tm1.1 mrl allele has 
exon 3 flanked by loxP sites. Slc39a8tm1.2 mrl allele was generated by Cre-mediated 
loxP site recombination resulting in the removal of the third exon of Slc39a8. It deleted 
the N-terminal part of the ZIP domain and the first 2 transmembrane domains, and 
generated a premature stop codon predicted to result in a protein null. Albumin-Cre 
mice, which express Cre under the control of the liver-specific Albumin promoter 
beginning from postnatal day 7, were obtained from the Jackson Laboratory (stock 
number 003574) and crossed with C57BL/6-Slc39a8tm1.1 mrl mice to generate Slc39a8 
liver-specific knockout. UBC-Cre/ERT2 mice, which express Cre and tamoxifen receptor 
ERT2 fusion protein under the control of the Ubiquitin promoter, were obtained from the 
Jackson Laboratory (stock number 007001), crossed with C57BL/6-Slc39a8tm1.1 mrl 
mice and injected with tamoxifen (100mg/kg) for 5 consecutive days to generate Slc39a8 
inducible knockout. To induce long-term Slc39a8 deletion, Slc39a8fl/fl; UBC-Cre/ERT2 
mice were fed with a tamoxifen citrate diet (360mg/kg, Animal Specialties and 
Provisions, DYE611574) for 5 weeks (168). Slc39a8tm1.1 mrl allele was detected by 
PCR using the following primers: 2476_27: 5ʼ-CAGGGTTTCTCTGTGTAACAGG-3ʼ; 
2475_28: 5ʼ-AGTGTACAGGCTCCAGCTACC-3ʼ. Slc39a8tm1.2 mrl was detected by 
PCR using the following primers: 2476_27: 5ʼ-CAGGGTTTCTCTGTGTAACAGG-3ʼ; 
2475_32: 5ʼ-CCAATATGGCCATAACAGATAGG-3ʼ. The Cre transgenic allele was 
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detected by PCR using the following primers: 1011_1: Cre_tot1_5ʼ-
ACGACCAAGTGACAGCAATG-3ʼ; 1011_2: Cre_tot2_5ʼ-CTCGACCAGTTTAGTTACCC-
3ʼ. To make AAV8 virus for liver-specific human ZIP8 or human ZIP8 A391T over-
expression, the SLC39A8 cDNA or SLC39A8 cDNA carrying the minor allele of 
rs13109325 generated by site-directed mutagenesis using primers SLC39A8-QC-F: 5ʼ-
GGTGGGCAACAATTTCACTCCAAATATTATATTTGCAC-3ʼ and SLC39A8-QC-R: 5ʼ-
GTGCAAATATAATATTTGGAGTGAAATTGTTGCCCACC-3ʼ	  were sub-cloned into a 
specialized AAV8 vector provided by the University of Pennsylvania Vector Core. These 
constructs, together with a chimeric packaging construct in which the AAV2 rep gene 
was fused with the cap gene of AAV8, were used to produce AAV8 viral particles 
expressing human ZIP8 or human ZIP8 A391T in the University of Pennsylvania Vector 
Core. AAV8 viral particles carrying an empty vector (AAV-Null) were also produced by 
the core. The mice were injected intraperitoneally with AAV at a dose of 1x1010 or 1x1011 
genome copies per mouse. Experiments were performed 4 weeks after AAV injection. 
Animals were fasted for 4 hours before being sacrificed for bile collection. To induce Cd 
accumulation, mice were treated with 100 mg/ml CdCl2 H2O for 8 weeks followed by 200 
mg/ml CdCl2 H2O for 4 weeks.  
 
Metal ion determination. Mn, Zn, and Fe in the bile and blood and Cd in tissues were 
measured using an Elan 6100 ICP-MS (inductively coupled plasma mass spectrometry) 
(Perkin Elmer, Shelton, CT) at the PADLS New Bolton Center Toxicology Laboratory, 
School of Veterinary Medicine of the University of Pennsylvania, as was previously 
described (169). For each bile sample, bile from two animals were combined. Weight 
and/or volume were recorded before measurements. For each measurement, the 
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sample was digested overnight with twice the amount (weight/volume) of 70% nitric acid 
at 70°C and 0.15 ml of the digested sample was diluted with deionized water to a final 
volume of 5 ml for analysis. The concentration was measured using a calibration curve 
of aqueous standards prepared at four different concentrations of each metal. Results 
were reported in ppm on a weight basis. Concentrations were calculated by dividing total 
amount by volume. 
 
The large excess of Fe (> 400 ppm) in a whole blood sample results in inaccurate ICP-
MS measurement of trace quantities of Mn (<0.1 ppm), due to isotopic interference of Fe 
at the mass of 55 that is used to measure Mn. Mn results were corrected using a formula 
created by the Toxicology Laboratory based on data obtained by performing experiments 
with certified bovine serum from Sigma Aldrich. This serum contains 2-3 ppm Fe that has 
a negligible effect on Mn results. The serum was spiked with Fe at concentrations of 
200, 400, and 600 ppm and these samples were analyzed using a PerkinElmer NexION 
300D ICP-MS. Based on the results obtained for Fe and Mn (in ppm), a Mn: Fe ratio was 
calculated for each spiked concentration using the following formula (Formula 1): 
Mn: Fe ratio = (observed Mn in spiked sample – observed Mn in control sample)/ 
(observed Fe in spiked sample – observed Fe in control sample) 
This experiment was repeated on three additional days. A water sample was also spiked 
with Fe at 200, 400, and 600 ppm to obtain a Mn interference measurement. The 
average ratios obtained from the three serum samples and one water sample, using 
Formula 1, were calculated at each level and plotted against the spiked concentrations 
of Fe. The linear regression equation obtained below was used to calculate a correction 
factor (CF). 
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CF = 6.55E-08 * x + 0.000364  
* is the symbol for multiplication and x is the concentration of iron measured in the test 
sample 
The CF obtained from the above equation was then used to calculate the corrected Mn 
value using the following formula: 
corrected Mn = observed Mn - CF * x 
* is the symbol for multiplication and x is the concentration of iron measured in the test 
sample  
 
Mn, Zn, and Fe in the liver, kidney, brain, heart and small intestine were measured using 
a Spectro ICP-OES (inductively coupled plasma optical emission spectrometry) in the 
Department of Earth and Environmental Science, School of Arts and Sciences, 
University of Pennsylvania, as was previously described (170). Samples were weighted, 
digested with 800 µl of HNO3: HCl [3:1] at 70°C overnight and diluted to a final volume of 
2.5 ml for analysis. The concentration was measured using a calibration curve of 
aqueous standards prepared at five different concentrations of each metal. Results were 
reported in ppm on a volume basis. Total amount determined by multiplying 
concentration with volume was divided by the wet weight of the tissue to obtain metal 
amount per mg of the tissue.    
 
Metal ion uptake study. HEK293T cells were seeded in 24-well plates and transfected 
using Lipofectamine 2000 (Invitrogen) the next day at a density of approximately 80% 
confluence. 24 hours after transfection, the cells were washed once with HBSS (Ca2+, 
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Mg2+ free) and incubated with pre-warmed uptake buffers at 37°C for 15 minutes. The 
15-minute time-point had been shown by a pilot study to be within the linear phase of 
metal ion uptake by ZIP8. To terminate the uptake, uptake buffer was removed and cells 
were washed with cold HBSS (Ca2+, Mg2+ free) three times. 500 µl NaOH (1mM) was 
added into each well to digest the cells. At least 2 hours later, 300 µl cell lysate was 
removed for liquid scintillation counting and 50 µl was used for protein measurement 
using BCA. For 54Mn uptake assay, uptake buffer was made by diluting MnCl2 (10 µM, 4 
µCi/ml) 1, 1.3, 2, 4, 10, and 40 times. For 65Zn uptake assay, uptake buffer was made by 
diluting ZnCl2 (5 µM, 1 µCi/ml) 1, 5, 25, and 100 times. For 109Cd uptake assay, uptake 
buffer was made by diluting CdCl2 (50 mM, 1 mCi/ml) 1, 2, 5, and 10 times.  
 
N-glycan profile analysis. Serum or plasma N-glycan profile analysis was performed 
as was previously described (171). In brief, serum samples pooled from 5 mice of the 
same genotype were digested with PNGase F at 37°C overnight to release N-glycans 
from total glycoproteins. The released N-glycans were purified with a C18 column 
followed by a carbograph column. The purified N-glycans were permethylated by a 
traditional liquid-liquid permethylation method and desalted by organic extraction with 
chloroform and water. Finally, permethylated N-glycan sodium adducts were analyzed by 
MALDI-TOF-MS to obtain N-glycan profiles. The percent total abundance of a glycan 
species corresponding to a peak in the chromatogram was calculated by dividing the 
area under the peak by the area under all of the peaks. 
 
β-1, 4-galactosyltransferase activity assay. The activity was performed with a UDP-
galactosyltransferase assay kit (Sigma, CS1050-1KT) and UDP-[6-3H]galactose 
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(American Radiolabeled Chemicals (ARC) ART 0131-250 µCi) to measure the transfer of 
radioactively labeled galactose from UDP-[6-3H]galactose to N-acetyl-D-glucosamine by 
UDP-galactosyltransferase. For sample preparation, 100 µg liver was homogenized in 4x 
volume of buffer (50 mM HEPES, 150 mM NaCl, 10% glycerol, 1% triton X-100) (172) 
with 1x protease/phosphatase inhibitor cocktail using a glass homogenizer for 
approximately 10 strokes and the lysate was centrifuged at 20000g for 20 minutes at 
4ºC. The supernatant was stored at -80ºC and used for BCA assay and enzymatic 
activity assay. The test reaction (with acceptor) consisted of 5 µl assay buffer, 5 µl MnCl2 
solution of desired concentrations, 5 µl UDP-Gal solution (10 mM), 5 µl acceptor 
solution, 1 µl UDP-[6-3H]galactose (1 µCi), 1.5 µl liver lysate supernatant (50-100 µg) 
and H2O to a total volume of 10 µl. A background control (without acceptor) was 
performed in parallel. The reaction was incubated at 37°C for 1 hour and stopped by 
addition of 100 µl ice-cold H2O. The reaction product, a radiolabeled N-acetyl-D-
lactosamine was then purified by ion-exchange chromatography and the radioactivity in 
the eluate was quantified by liquid scintillation counting. β-1, 4-galactosyltransferase 
specific activity was defined according to the instructions of the manufacturer of the kit.  
 
MnSOD activity assay. Supernatant prepared as was described in the β-1, 4-
galactosyltransferase activity assay was diluted 3 x and incubated with 10 mM KCN at 
room temperature for 30 minutes to inhibit the activity of CuSOD and ZnSOD. A series of 
5x dilutions were made to generate the inhibition curve of the SOD assay kit (Dojindo, 
S311-10), which measured the inhibition of the reduction of WST, a highly water-soluble 
tetrazolium salt, with the superoxide anion by SOD in the liver lysate. One unit of SOD 
was defined as the amount of enzyme in 20 µl of sample that inhibited the reduction 
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reaction by 50%. The enzymatic unit was normalized to the protein content determined 
by BCA.  
 
Immunoblot analysis. 50 mg of liver was homogenized in 4x volume of PBS with 
protease and phosphatase inhibitor. Lysate was centrifuged at 4ºC at 14,000 x g for 15 
minutes and the supernatant was used for immunoblot analysis. 50 µg protein was 
separated via the NuPage SDS Page system (Invitrogen). Primary antibodies used were 
anti-ZIP8 (1:1000, Proteintech 20459-1-AP), anti-arginase I (1:2500, BD Biosciences 
610708) and anti-β actin (1:1000, Santa Cruz sc-81178). HRP-conjugated anti-rabbit 
and anti-mouse secondary antibodies (1:2500, Roche Applied Science) and the Classico 
ECL reagent (Millipore) were used to visualize the signal. 
 
Immunofluorescence. Liver pieces were frozen in OCT and cut into sections of 8 µm 
thick in the Histology and Gene Expression Core of the Cardiovascular Institute of the 
University of Pennsylvania. Immunofluorescence was performed in the core using the 
following antibodies: anti-Zip8 (1:50, Sigma HPA038832) and anti-Mdr (C-19) (1:2500, 
Santa Cruz sc-1517).  
 
qRT-PCR. RNA was isolated using Trizol and cDNA was made using High Capacity 
cDNA Reverse Transcription Kit (Applied Biosystems). Fast SYBR Green Mastermix 
(Life Technologies, 4385614) was used for real-time PCR analysis. SYBR primers used 
were: Slc39a8-F: 5ʼ-CAACGCAAAGCCCAGTCTTT-3ʼ; Slc39a8-R: 5ʼ-
GCGTTTGAGAAAAGAGTCCCAA-3ʼ; SLC39A8-F: 5ʼ-TTCCAGAGGCATTTGGATTT-3ʼ; 
30 
SLC39A8-R: 5ʼ-GGGTATGACCATTCTGACCAT-3ʼ; Gapdh-F: 5ʼ-
TGTGTCCGTCGTGGATCTGA-3ʼ; Gapdh-R: 5ʼ-CCTGCTTCACCACCTTCTTGAT-3ʼ.  
Statistical analyses. Comparisons of two samples were performed using two-tailed 
Studentʼs t-test. Multiple comparisons were performed using one-way ANOVA and 
Tukey's multiple comparison test. Multiple comparisons of different treatments were 
performed using two-way ANOVA and Bonferroniʼs multiple comparison test. 
Comparison of the frequency of the truncated N-glycan was performed using Chi-square 
test. Correlation analyses were performed using Pearson test. A p-value of less than 
0.05 was considered significant. 
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Results 
Inducible global Slc39a8 deletion leads to systemic Mn deficiency. 
SLC39A8 is widely expressed (63). To study the physiological effects of SLC39A8 
deficiency, I generated inducible global Slc39a8 knockout mice by crossing conditional 
ʻfloxedʼ Slc39a8 mice (Slc39a8flox/flox) with UBC-Cre/ERT2 transgenic mice. Slc39a8 
deletion was induced by tamoxifen administered either by injection or as dietary 
tamoxifen citrate. Real-time PCR (qPCR) analysis revealed that, compared with control 
Slc39a8flox/flox mice injected with tamoxifen (WT), Slc39a8flox/flox; UBC-Cre/ERT2 mice 
injected with tamoxifen (hereafter referred to as Zip8 iKO) had efficient Slc39a8 deletion 
in the liver (-98%, p<0.001), kidney (-98%, p<0.001), brain (-51%, p=0.034), heart (-88%, 
p<0.001) and small intestine (-98%, p<0.001) (Figure 1A). Despite the known ability of 
Zip8 to transport Zn and Fe, tissue Zn and Fe levels were not different in Zip8 iKO mice 
compared with controls (Table I). In contrast, tissue Mn levels in  Zip8 iKO mice were 
markedly reduced. Compared with control mice, Mn was decreased in the liver (-77%, 
p<0.001), kidney (-52%, p<0.001), brain (-31%, p<0.001) and heart (-27%, p=0.008) of 
Zip8 iKO mice (Figure 1B and Table I). This observation is consistent with the findings 
that patients carrying SLC39A8 mutations develop severe deficiency in Mn but not Zn, 
that SLC39A8 variants are associated with whole blood Mn but not Zn, and that Zip8 
was shown to have high affinity for Mn but not Zn in mammalian cells.  
 
Slc39a8 has been implicated in Cd accumulation in the testicular vasculature and renal 
proximal tubule cells of mouse and the lung epithelia of human. Therefore, I induced 
Slc39a8 deletion in Slc39a8fl/fl; UBC-Cre-ERT2 mice with a tamoxifen citrate diet (Zip8 
iKO) and treated the mice with CdCl2 water to see whether Slc39a8 deletion would 
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protect mice against Cd accumulation. Slc39a8fl/fl treated with the tamoxifen citrate diet 
were used as control (WT). WT and Zip8 iKO mice on CdCl2 treatment had dramatically 
increased Cd in the liver, kidney, heart, and testes compared with mice on water 
treatment, and there was a moderate decrease of Cd in the kidney of Zip8 iKO/Cd mice 
compared with the WT/Cd (-18.9%, p=0.028) (Figure 1E and F). These observations 
suggested that Slc39a8 may not play a major role in Cd transport in the organs 
examined, at least when examined in the whole-organ level. 
 
Given the association of the SLC39A8 locus with HDL-C and BMI, I compared body 
weights of Zip8 iKO mice (induced by tamoxifen injection) with the control mice on chow 
and western diet and did not observe significant differences. Detailed characterization of 
the HDL-C phenotype can be found in Chapter 4. There were no overt neurological or 
skeletal abnormalities in the Zip8 iKO mice compared with the control mice.  
 
Consistent with systemic Mn deficiency of Zip8 iKO mice, Slc39a8 heterozygous mice 
(hereafter referred to as Zip8 Het), which had decreased Slc39a8 expression in the liver 
(-44%, p<0.001), kidney (-44%, p=0.006) and brain (-24%, p=0.04) (Figure 1C), also had 
significantly decreased Mn in these organs, though to a lesser extent than in the Zip8 
iKO mice. In Zip8 Het mice, Mn was reduced by -39% in the liver (p=0.003), -32% in the 
kidney (p<0.001), -23% in the brain (p=0.002), and -14% in the heart (p=0.021) (Figure 
1D); in contrast, Mn was increased by +34% in the small intestine (p=0.004), despite 
decreased Slc39a8 expression in this organ (-51%, p=0.014). 
33 
 
Figure 1. Global Slc39a8 deletion leads to systemic Mn deficiency (A) Real-time 
PCR (qPCR) analysis of Slc39a8 expression in male Slc39a8fl/fl (WT) and Slc39a8fl/fl; 
UBC-Cre/ERT2 (Zip8 iKO) mice injected with tamoxifen at 8 weeks of age and sacrificed 
5 weeks after the injection. n=3-6. (B) ICP-OES analysis of Mn in male Slc39a8fl/fl and 
Slc39a8fl/fl; UBC-Cre/ERT2 mice injected with tamoxifen at 8 weeks of age and sacrificed 
5 weeks after the injection. n=5-6. (C) qPCR analysis of Slc39a8 expression in 12-14 
weeks old male WT and Zip8 Het mice. n=4-6. (D) ICP-OES analysis of Mn in 12-14 
weeks old male WT and Zip8 Het mice. n=4-5. (E-F) ICP-MS analysis of Cd in male 
Slc39a8fl/fl and Slc39a8fl/fl; UBC-Cre/ERT2 mice fed with a 5-week tamoxifen citrate diet 
at 8 weeks of age and sacrificed after 10 weeks of H2O or H2O with CdCl2 treatment. 
N=3-4. qPCR results were normalized to Gapdh. ICP-OES and ICP-MS results were 
normalized to wet tissue weight. Mn levels in the tissues were normalized to the average 
of the control group. Absolute Mn content can be found in Table I. All data are shown as 
the mean ± SD. Results were analyzed using Studentʼs t-test (***p ≤ 0.001, **p ≤ 0.01, *p 
≤ 0.05). 
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Hepatic Zip8 regulates whole body Mn homeostasis.  
The liver plays a vital role in regulating Mn homeostasis in vivo (116). In order to 
determine the contribution of hepatic Zip8, I generated Slc39a8 liver-specific knockout 
mice by crossing Slc39a8flox/flox mice with Alb-Cre transgenic mice. Compared with 
control Slc39a8flox/flox mice, Slc39a8flox/flox; Alb-Cre mice (hereafter referred to as Zip8 
LSKO) had decreased Slc39a8 mRNA in the liver (-75%, p<0.001) but normal Slc39a8 
expression in other tissues (Figure 2A). Mn levels were not only substantially decreased 
in the liver (-69%, p<0.001), but also in the kidney (-49%, p<0.001), brain (-34%, 
p<0.001), and heart (-47%, p<0.001), indicating that hepatic Slc39a8 deletion decreased 
Mn levels in extra-hepatic tissues (Figure 2B). To confirm that the regulation of Mn by 
Slc39a8 is not specific to male mice, I examined Mn in the liver and kidney of female 
Zip8 LSKO mice and also observed decreased Mn compared with the control mice (-
76% p<0.001 for liver and -57%, p<0.001 for kidney). In addition, whole blood Mn was 
decreased in Zip8 LSKO mice (-65%, p=0.002) (Figure 2C). As with the Zip8 iKO mice, 
compared to controls LSKO mice exhibited no significant differences in bodyweight and 
no overt neurological or skeletal abnormalities. Detailed examination of the HDL-C 
phenotype can be found in Chapter 4.  
 
In order to test whether human ZIP8 could compensate for the absence of murine Zip8, I 
injected an AAV vector expressing human SLC39A8/ZIP8 under the control of a liver-
specific promoter (hereafter referred to as AAV-ZIP8) into Zip8 LSKO mice. Expression 
of human ZIP8 in liver restored the Mn levels in the liver and kidney (Figure 2D).  
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To determine whether hepatic expression of human SLC39A8/ZIP8 regulates whole-
body Mn homeostasis over a wider range of expression, I injected wild-type mice with 
AAV-ZIP8. Human SLC39A8 mRNA was only detectable in the liver and not other 
tissues (data not shown). Western blot analysis confirmed that AAV-ZIP8 mice 
expressed human ZIP8 protein in the liver (Figure 2E). Mn was significantly increased in 
the liver (+87%, p<0.001), kidney (+22%, p=0.002), brain (+21%, p<0.001), heart (+22%, 
p<0.001), and small intestine (+28%, p=0.04) (Figure 2F), indicating that liver-specific 
human ZIP8 over-expression increased systemic tissue Mn levels. Mn was also 
increased in the whole blood (+94%, p<0.001) (Figure 2G). Neither Zn nor Fe levels 
were changed in the tissues (Table I) or whole blood (Table II) of Zip8 LSKO or AAV-
ZIP8 mice compared with corresponding controls.  
 
I examined the correlation between hepatic Mn level and Mn levels in the kidney, brain, 
heart, small intestine and whole blood, using data generated from these experiments. 
There was a linear correlation between hepatic Mn and Mn in the kidney (r=0.8677, 
p<0.001), brain (r=0.8483, p<0.001), heart (r=0.8427, p<0.001) (Figure 2H), and whole 
blood, (r=0.9138, p=0.001) (Figure 2I). These results provide strong evidence that 
hepatic expression of Zip8 specifically and quantitatively regulates whole-body 
homeostasis of Mn, but not Zn or Fe, over a wide range of expression. 
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Figure 2. Hepatic Zip8 regulates whole-body Mn homeostasis (A) qPCR analysis of 
Slc39a8 expression in 12-14 weeks old male Slc39a8fl/fl (WT) and Slc39a8fl/fl; Alb-Cre 
mice (Zip8 LSKO). n=3-4. (B) ICP-OES analysis of Mn in 12-14 weeks old male 
Slc39a8fl/fl  and Slc39a8fl/fl; Alb-Cre mice. n=4. (C) ICP-MS analysis of Mn in the whole 
blood of 14-16 weeks old male Slc39a8fl/fl and Slc39a8fl/fl; Alb-Cre mice. n=7 and 6. (D) 
ICP-OES analysis of Mn in 12-14 weeks old male Slc39a8fl/fl mice injected with AAV-Null 
and Slc39a8fl/fl; Alb-Cre mice injected with AAV-Null or AAV-ZIP8. n=3-6. (E) Western 
blot analysis of ZIP8 in the liver lysate of male B6 mice injected with AAV-Null or AAV-
ZIP8 at 10 weeks of age and sacrificed 4 weeks after injection. Arrows indicate ZIP8 
bands. (F) ICP-OES analysis of Mn in male B6 mice injected with AAV-Null or AAV-ZIP8 
at 10 weeks of age and sacrificed 4 weeks after injection. n=6. (G) ICP-MS analysis of 
Mn in the whole blood of male B6 mice injected with AAV-Null or AAV-ZIP8 at 8 weeks 
of age and sacrificed 4 weeks after injection. n=5 and 4. qPCR results were normalized 
to Gapdh. ICP-OES results were normalized to wet tissue weight. Mn levels were 
normalized to the average of the control group. Absolute Mn content can be found in 
Table I. All data are shown as the mean ± SD. Comparisons between two groups were 
performed using Studentʼs t-test. Multiple comparisons in Figure 2D were performed 
using one-way ANOVA and Tukeyʼs multiple comparison test. ***p ≤ 0.001, **p ≤ 0.01, *p 
≤ 0.05. (H) Correlation analyses between hepatic Mn and Mn in the kidney, brain and 
heart of WT and Zip8 LSKO mice and AAV-Null and AAV-ZIP8 mice. n=19. (I) 
Correlation analysis between hepatic Mn and Mn in the whole blood of WT and Zip8 
LSKO mice and AAV-Null and AAV-ZIP8 mice. n=22. Mn levels were normalized to the 
average of the control group. Results were analyzed using Pearson test. 
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Zip8 reclaims Mn from the bile.  
Zip family members are known to import metal ions into the cytosol and previous studies 
showed that mouse Zip8 promoted the uptake of Mn in fetal fibroblasts (72) and kidney 
proximal tubule cells (73). I tested the ability of human ZIP8 to promote uptake of Mn into 
mammalian cells. Expression of human ZIP8 in HEK293T cells resulted in significantly 
increased cellular Mn uptake (Figure 3C), confirming its role in cellular Mn uptake. The 
major route of Mn disposal is biliary excretion, where hepatocytes export Mn across the 
apical membrane into bile canaliculi (113, 114). I hypothesized that Zip8 is localized to 
the hepatocyte apical canalicular membrane and functions to reclaim Mn from the bile by 
promoting its reuptake into hepatocytes. Immunofluorescence analysis of mouse liver 
sections revealed that in WT hepatocytes Zip8 co-localizes with the multiple drug 
resistance-associated protein (Mdr1), a well-established canalicular membrane marker, 
and was undetectable in hepatocytes from Zip8 LSKO mice (Figure 3A). Zip8 was also 
detected on the apical membrane of cholangiocytes, the columnar epithelial cells of the 
bile duct, where it may further reclaim Mn from the bile (Figure 3B). Consistent with this 
model, Zip8 LSKO mice had increased Mn in the bile (+55%, p<0.001) (Figure 3D) 
despite reduced liver and other tissue Mn, and conversely, AAV-ZIP8 mice had 
decreased Mn in the bile (-76%, p<0.001) (Figure 3E) despite increased liver and other 
tissue Mn. Zn and Fe were not changed in the bile of Zip8 LSKO or AAV-ZIP8 mice 
(Table III). These observations combined strongly support a model whereby Zip8 is 
localized to the apical surface of the hepatocyte and reclaims Mn (but not Zn or Fe) from 
the bile, reducing its biliary excretion and defending whole-body Mn stores.  
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Figure 3. Zip8 reclaims Mn from the bile (A-B) Immunofluorescence analysis of Zip8 
(green) and Mdr1 (magenta) localization in Slc39a8fl/fl and Slc39a8fl/fl; Alb-Cre mouse 
liver sections. Arrows indicate bile duct. The result is representative of 3 independent 
experiments. (C) 54Mn uptake study of HEK293T cells over-expressing human ZIP8. 
N=3. (D) ICP-MS analysis of Mn in the bile of 12-14 weeks old male Slc39a8fl/fl and 
Slc39a8fl/fl; Alb-Cre mice. n=4. (E) ICP-MS analysis of Mn in the bile of male B6 mice 
injected with AAV-Null or AAV-ZIP8 at 10 weeks of age and sacrificed 4 weeks after 
injection. n=6 and 5. Scale bar: 10 um. All data are shown as the mean ± SD. Results 
were analyzed using Studentʼs t-test (***p ≤ 0.001, **p ≤ 0.01, *p ≤0.05).  
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A391T does not impair metal ion transport by ZIP8. 
A391T was predicted to be damaging to ZIP8 function in silico and was experimentally 
shown to impair Cd and Zn uptake by ZIP8 in vitro (59, 60). I examined metal ion uptake 
by ZIP8 A391T in vitro and in vivo. After generating plasmids that can express ZIP8 
A391T in cells (PK1-ZIP8 A391T) and plasmids that can be used to produce AAV8 
vector expressing ZIP8 A391T (AAV-ZIP8 A391T), I sequenced the plasmids to confirm 
the presence of the minor allele that would result in the amino acid change (Figure 4A). 
Western blot analysis showed comparable protein levels of ZIP8 and ZIP8 A391T, when 
PK1-ZIP8 and PK1-ZIP8 A391T were over-expressed in HEK293T cells and when AAV-
ZIP8 and AAV-ZIP8 A391T were over-expressed in mouse liver (Figure 4B). In vitro 
metal ion radioactive isotope uptake studies demonstrated that ZIP8 and ZIP8 A391T 
had similar ability to transport Mn, Zn, and Cd when over-expressed in HEK293T cells 
(Figure 4C-E). Furthermore, AAV-ZIP8 and AAV-ZIP8 A391T exhibited similar ability to 
restore hepatic Mn, kidney Mn, and hepatic arginase activity of Zip8 LSKO mice when 
over-expressed in vivo (Figure 4F-H). Lowering the dose of the AAV8 virus decreased 
the degree of rescue but did not bring out a difference between ZIP8 and ZIP8 A391T 
(Figure 4I-K).  
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Figure 4. A391T does not impair metal ion transport by ZIP8 (A) Sequencing results 
of ZIP8 expression plasmids and plasmids used to produce AAV virus. (B) Western blot 
of ZIP8 and ZIP8 A391T when over-expressed in cells and mouse liver. (C-E) Uptake 
studies of 54Mn, 65Zn, and 109Cd by ZIP8 and ZIP8 A391T when over-expressed in 
HEK293T cells. Cells were incubated with 0.5 µM MnCl2 in C. n=3. (F-H) Hepatic Mn, 
kidney Mn, and hepatic arginase activity of WT and Zip8 LSKO mice injected with AAV-
Null, AAV-ZIP8, or AAV-ZIP8 A391T at a dose of 1x1011 GC/mouse. (I-K) Hepatic Mn, 
kidney Mn, and hepatic arginase activity of WT and Zip8 LSKO mice injected with AAV-
Null, AAV-ZIP8, or AAV-ZIP8 A391T at a dose of 1x1010 GC/mouse. All data are shown 
as the mean ± SD. Comparisons between two groups were performed using Studentʼs t-
test. ***p ≤ 0.001, **p ≤ 0.01, *p ≤0.05.  
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Zip8 acts through Mn to modulate protein N-glycosylation.   
β-1,4 galactosyltransferase is a Mn-dependent enzyme that requires Mn for substrate 
binding and catalytic activity. It catalyzes the transfer of galactose to the glycan moiety of 
protein during protein N-glycosylation (173), while Mn deficiency has been found to 
impair protein N-glycosylation, especially galactosylation (90). Moreover, patients 
carrying SLC39A8 mutations have severe Mn deficiency and defective protein N-
glycosylation with prominent hypogalactosylation (77-79). I examined the N-glycan 
profile in the serum of Slc39a8 loss-of-function mouse models using matrix-assisted 
laser desorption/ionization (MALDI)/time-of-flight (TOF) mass spectrometry analysis 
(Figure 5 A-D). Compared with control mice, Zip8 iKO mice had decreased abundance 
of fully glycosylated N-glycan species (26.6% in WT vs. 16.2% in Zip8 iKO) and 
increased abundance of truncated N-glycan species, especially under-galactosylated N-
glycan species including monosialo-monogalacto-biantennary glycans (1.0% in WT vs. 
3.7% in Zip8 iKO), asialo-monogalacto-biantennary glycans (0 in WT vs. 1.7% in Zip8 
iKO), and asialo-agalacto-biantennary glycans (0 in WT vs. 1.4% in Zip8 iKO). Similarly, 
compared with control mice, Zip8 LSKO mice had decreased abundance of fully 
glycosylated N-glycan species (41.0% in WT vs. 35.5% in Zip8 LSKO) and increased 
abundance of truncated N-glycan species, especially under-galactosylated N-glycan 
species monosialo-monogalacto-biantennary glycans (0.7% vs. 2.6%). Mn deficiency 
has also been found to moderately impair N-acetyl-glucosaminylation mediated by 
another Mn-dependent glycosyltransferase, N-acetyl-glucosaminyltransferase II (90, 
174). In agreement with this, Zip8 iKO mice had reduced N-acetyl-glucosaminylation 
shown by increased abundance of under-N-acetyl-glucosaminylated N-glycan species 
including monosialo-monogalacto-mono-GlcNAc-biantennary N-glycans (0 in WT vs. 
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0.8% in Zip8 iKO) and asialo-agalacto-mono-GlcNAc-biantennary N-glycans (0 in WT vs. 
1.5% in Zip8 iKO). These patterns are consistent with reduced activity of the Mn-
dependent enzymes β-1, 4-galactosyltransferase and N-acetyl-glucosaminyltransferase 
II.   
 
In order to directly examine β-1, 4-galactosyltransferase activity, I set up an enzymatic 
activity assay that measures the transfer of galactose to N-acetyl-glucosamine by β-1, 4-
galactosyltransferase. β-1, 4-galactosyltransferase activity was undetectable without 
addition of MnCl2, and there was no difference in the enzymatic activity between WT and 
Zip8 iKO mouse liver when 10 mM of MnCl2 was added to the assay (Figure 5E).  
 
The lead variant in SLC39A8 associated with lower whole blood Mn and other pleiotropic 
traits is the coding variant rs13107325 (Ala391Thr) that is associated with lower hepatic 
SLC39A8 expression (50, 52) and may encode a protein with reduced function (59, 60).  
I examined the N-glycan profile in the plasma of rs13107325 A391T homozygotes and 
matched major allele homozygotes. Under-galactosylated N-glycan species monosialo-
monogalacto-biantennary glycans were detected in 58% of the minor allele homozygotes 
and only in 18% of the major allele homozygotes (p=0.049). The abundance of 
monosialo-monogalacto-biantennary glycans was higher in the minor allele homozygotes 
compared with the homozygous major allele carriers (p=0.047; Figure 5F). These results 
indicate that homozygotes for the minor allele had reduced activity of the Mn-dependent 
β-1, 4-galactosyltransferase consistent with the association of the minor allele with lower 
blood Mn. 
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Figure 5. Slc39a8 loss-of-function results in protein N-glycosylation defects (A and 
B) MALDI-TOF analysis of N-glycan profile of serum obtained 5 weeks after male 
Slc39a8fl/fl and Slc39a8fl/fl; UBC-Cre/ERT2 mice were injected with tamoxifen at 8 weeks 
of age. (C and D) MALDI-TOF analysis of N-glycan profile of serum obtained from 10-12 
weeks old male Slc39a8fl/fl and Slc39a8fl/fl; Alb-Cre mice. Each sample was pooled from 
5 mice of the same genotype. White diamond: sialic acid; yellow circle: galactose; blue 
square:	  N-acetyl-glucosamine; green circle: mannose. The numbers above the peaks 
indicate the mass-to-charge ratios of the N-glycan species. 2853: disialo-biantennary 
glycans; 2448: monosialo-digalacto-biantennary glycans; 2257: monosialo-monogalacto-
biantennary glycans; 1852: asialo-monogalacto-biantennary glycans; 1661: asialo-
agalacto-biantennary glycans; 1416: asialo-agalacto-mono-GlcNAc-biantennary N-
glycan. (E) β-1, 4-galactosyltransferase (β4GalT1) activity assay of liver lysate 
harvested 5 weeks after male Slc39a8fl/fl and Slc39a8fl/fl; UBC-Cre/ERT2 mice were 
injected with tamoxifen at 8 weeks of age. N=3. (E) Abundance of monosialo-
monogalacto-biantennary glycans in the plasma of rs13107325 major and minor allele 
homozygotes. N=11 and 12. Data are shown as the mean ± SD. Comparison was 
performed using Studentʼs t-test. *p ≤0.05. 
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Slc39a8 deletion does not decrease the activity of MnSOD. 
Manganese superoxide dismutase (MnSOD) is a Mn metalloenzyme that contains tightly 
bound Mn ions (175). The dismutase activity protects cells against the deleterious effects 
of reactive oxygen species generated by mitochondrial respiration (176). MnSOD activity 
was measured in the liver lysate of WT and Zip8 iKO mice, and efficient Slc39a8 
deletion was confirmed in the liver of the Zip8 iKO mice (Figure 6A). MnSOD in the liver 
lysate inhibited a reductive reaction with superoxide anion (Figure 6B). Enzymatic 
activity calculated based on the IC50 of the reaction was not different between WT and 
Zip8 iKO mouse liver lysate (Figure 6C). 
 
Figure 6 Slc39a8 deletion does not decrease the activity of MnSOD (A) qRT-PCR of 
Slc39a8 in male Slc39a8fl/fl and Slc39a8fl/fl; UBC-Cre/ERT2 mice injected with tamoxifen 
at 8 weeks of age and sacrificed 5 weeks later. N=5. (B) Inhibition of a reductive reaction 
with the superoxide anion by MnSOD in the liver lysate of mice from A. Blue: Slc39a8fl/fl. 
Red: Slc39a8fl/fl; UBC-Cre/ERT2. The number represents the sample ID. (C) MnSOD 
activity of mouse livers calculated based on the IC50 obtained from (B). N=5. All data 
are shown as the mean ± SD. ***p ≤0.001 
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Discussion 
This project was spurred by the observations that genetic variants, including a coding 
variant, in the gene SLC39A8 are associated with whole blood Mn levels and multiple 
physiological traits (1)(2-8). I used several Slc39a8 loss-of-function and gain-of-function 
mouse models to gain insight into the role of Zip8 in Mn metabolism and how it relates to 
Mn-dependent enzyme activity and the physiological role of Zip8. My study reveals a 
novel role of hepatic Zip8 in regulating whole-body Mn homeostasis, the activity of a Mn-
dependent glycosyltransferase, and protein N-glycosylation. I discovered that hepatic 
Zip8 regulates Mn metabolism in the liver, which in turn regulates Mn content in other 
organs and tissues, including kidney, brain, heart and whole blood. I demonstrated that 
Zip8 is localized to the hepatocyte canalicular membrane and functions to reclaim Mn 
from biliary excretion. I showed that Zip8 deletion in mice led to defective protein N-
glycosylation. Furthermore, I found that homozygosity for the minor allele of rs13107325 
(Ala391Thr) in SLC39A8, which has reduced expression or protein function, is 
associated with hypogalactosylation. These findings are consistent with decreased 
activity of a Mn-dependent glycosyltransferase, β-1, 4-galactosyltransferase. Therefore, 
these results demonstrate that hepatic ZIP8 regulates whole-body Mn homeostasis and 
influences protein N-glycosylation by modulating the activity of a Mn-dependent 
glycosyltransferase, potentially providing insights into the association of genetic variants 
at the SLC39A8/ZIP8 locus with physiological traits.  
 
The lead variant at SLC39A8 associated with whole blood Mn levels and physiological 
traits is a coding variant rs13107325 (Ala391Thr) that has an 8% minor allele frequency 
in people of European ancestry (9). The substitution of a threonine for alanine at the 391 
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residue of ZIP8 is predicted to be damaging to ZIP8 function in silico and was 
experimentally shown to impair cellular Cd and Zn uptake by ZIP8 (10)(11). Rs13107325 
is also an eQTL for SLC39A8 in human liver associated with reduced expression (4, 6). 
Importantly, this variant associated with lower hepatic SLC39A8 expression and reduced 
ZIP8 activity is associated with lower whole blood Mn levels (1).	  Furthermore, SLC39A8 
loss-of-function mutations were recently identified in human patients exhibiting 
neurological and skeletal symptoms (16-18), and these patients were found to have 
decreased whole blood Mn and reduced protein N-glycosylation especially 
galactosylation. Thus, the human data indicate that reduced expression and function of 
SLC39A8/ZIP8 lead to reduced whole blood Mn and protein N-glycosylation especially 
galactosylation, a directionality fully consistent with our findings in Slc39a8 loss-of-
function mice and rs13107325 homozygous minor allele carriers. 
 
One key finding of this study is the central role of ZIP8 in modulating biliary Mn 
excretion. Dmt1 has been believed to be the primary Mn transporter (125, 167), but it 
has been shown to be dispensable for Mn uptake in small intestine (126) and liver (125). 
The current model of Mn metabolism by the liver is that hepatocytes take up Mn from 
blood at the basolateral surface and excrete it to the bile at the apical surface. ZIP14, a 
close family member of ZIP8, may be responsible for uptake of Mn from blood, as it has 
been reported to be localized on the basolateral membrane of hepatocytes (127) and 
has affinity for Mn in vitro (64, 73). Furthermore, patients carrying SLC39A14 mutations 
exhibited excessive Mn accumulation in the whole blood and brain but a lack of Mn in 
the liver, potentially due to Mn bypassing hepatic uptake and subsequent biliary 
excretion in the absence of SLC39A14 (108). SLC30A10, a Mn exporter, is expressed in 
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the liver and may be the transporter that excretes Mn from hepatocytes into the bile 
canaliculi (107). I have shown for the first time that ZIP8 is localized to the apical 
canalicular membrane of the hepatocyte and promotes the reuptake of Mn from the bile 
into the hepatocyte, thus acting to defend against Mn deficiency. Importantly, I showed 
that hepatic Slc39a8 expression across a wide range from homozygous knockout to over 
expression is quantitatively associated with not only hepatic Mn levels but also Mn levels 
in blood and multiple other tissues. Thus my data indicate that hepatic ZIP8 is a 
quantitative regulator of whole-body Mn homeostasis. Zip8 iKO mice do not have greater 
tissue reductions in Mn than Zip8 LSKO mice, suggesting that hepatic Zip8 is the critical 
regulator of whole-body Mn homeostasis. Although Zip8 has been detected in the 
proximal tubule cells of the kidney and is suggested to take up metal ions from the filtrate 
(73), kidney Mn was not further decreased in Zip8 iKO mice.  
 
Mn deficiency caused by loss-of-function mutations of SLC39A8 results in CDG II and 
mitochondrial disease, and there is great interest in whether Mn supplementation is a 
viable treatment for the CDG II patients (17, 18). Mn intoxication caused by occupational 
exposure (177), parenteral nutrition (114, 178), liver disease (110), and SLC30A10 
mutation (107) has been shown to cause manganism characterized by neurological and 
behavioral disorders resembling Parkinsonʼs disease (98, 116). The discovery that ZIP8 
maintains whole-body Mn homeostasis by scavenging Mn from biliary excretion 
suggests that SLC39A8 may be a therapeutic target for inhibition in the treatment of Mn 
intoxication and provides rationale for Mn supplementation as a treatment of SLC39A8-
CDG patients.  
 
48 
It has been shown that A391T impairs Cd and Zn uptake by ZIP8, using 109Cd and 
Zinquin, a Zn fluorophore respectively. However, my in vitro study using radioactive 
isotopes did not reveal impaired Cd, Zn, or Mn uptake by ZIP8 A391T. It is worth noting 
that the buffer used in the radioactive isotope uptake studies, HBSS, has a low level of 
bicarbonate, while bicarbonate has been shown to be required for ZIP8 function. 
Therefore, it may worth trying adding bicarbonate into the uptake study and see how that 
affect ZIP8 and ZIP8 A391T activity. Nonetheless, ZIP8 A381T activity did not seem to 
decrease either in vivo, as it rescued hepatic Mn of Zip8 LSKO similarly to ZIP8 when 
over-expressed using AAV in mouse liver. Given that rs13107325 is an eQTL of 
SLC39A8 associated with lower transcript abundance in human liver, it is possible that it 
has a direct effect on SLC39A8 expression (for example by affecting the transcript 
stability) or that it is in LD with a non-coding regulatory SNP (and therefore absent in the 
recombinant expression constructs). 
 
β-1, 4-galactosyltransferase is a Mn-dependent enzyme that requires Mn for substrate 
binding and catalytic activity (166, 173). Mn deficiency resulted from mutations of 
SLC39A8 (17, 18) and TMEM165 (90) have led to protein N-glycosylation defects, 
especially hypogalactosylation indicative of decreased β-1, 4-galactosyltransferase 
activity. In addition, TMEM165 mutated patients (179) and knocked-down cells (90) 
exhibited impaired N-acetyl-glucosaminylation, another protein N-glycosylation step 
mediated by the Mn-dependent glycosyltransferase N-acetyl-glucosaminyltransferase II. 
Slc39a8 loss-of-function mice recapitulated the protein N-glycosylation defects resulted 
from Mn deficiency, including hypogalactosylation of SLC39A8-CDG (79) and 
TMEM165-CDG patients and hypo-N-acetyl-glucosaminylation of TMEM165-CDG 
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patients (179). In addition, I showed that hypogalactosylation is more common in 
rs13107325 A391T homozygous minor allele threonine carriers compared with 
homozygous major allele alanine carriers, consistent with the association of the minor 
allele with decreased whole blood Mn. Protein N-glycosylation affects the fate and 
function of proteins (180) and influences numerous physiological processes (181). Of 
particular interest to our group, it modulates the activity of key regulators of human HDL-
C metabolism (182-186) and has been implicated in dyslipidemia (183). Therefore, my 
findings suggest that protein N-glycosylation may be related to the association of 
SLC39A8 with HDL-C and potentially other physiological traits in GWAS.   
 
Patients carrying SLC39A8 mutations exhibited neurological and skeletal abnormalities 
evident very early in life (77-79). Zip8 iKO and Zip8 LSKO mice did not exhibit such 
abnormalities, but I suggest that the normal expression of SLC39A8 during development 
and the post-natal timing of gene deletion in these mouse models may be the major 
explanation for this difference. In fact, complete knockout of Slc39a8 is not compatible 
with live births of knockout mice. Although SLC39A8 variants are associated with BMI in 
GWAS, Zip8 iKO and Zip8 LSKO mice did not have overtly abnormal bodyweight on 
chow or western diet. More detailed investigation of the BMI trait in Slc39a8 mouse 
models will be required. Finally, I investigated the blood pressure and HDL-C 
phenotypes and potential regulatory mechanisms in Slc39a8 mouse models, which are 
described in Chapter 3 and 4 respectively.  
 
This project suggests a model in which hepatic expression of SLC39A8 has systemic 
effects on Mn homeostasis, β-1, 4-galactosyltransferase activity, and protein N-
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glycosylation (Figure 7). Hepatic ZIP8 scavenging of Mn from bile is the likely 
mechanism underlying the association of the SLC39A8 locus with whole blood Mn and 
the severe Mn deficiency of SLC39A8 mutated patients. The subsequent regulation of β-
1, 4-galactosyltransferase activity and protein N-glycosylation may be related to the 
association of SLC39A8 with other physiological traits in humans.  
 
 
Figure 7 Slc39a8/Zip8 influences protein N-glycosylation by regulation whole-
body Mn homeostasis Slc39a8/Zip8 reclaims Mn from biliary excretion to maintain 
whole-body Mn homeostasis and the activity of the Mn dependent enzyme β-1, 4-
galactosyltransferase. Under Slc39a8 loss-of-function, increased biliary excretion leads 
to systemic Mn deficiency. The subsequent decrease in the activity of β-1, 4-
galactosyltransferase results in hypogalactosylation of proteins, potentially including key 
regulators of HDL-C and other traits associated with SLC39A8 in GWAS. 
51 
Table I Tissue distribution of Mn, Zn, and Fe Slc39a8 mouse models 
  Mn (ng/mg) Zn (ng/mg) Fe (ng/mg) 
  WT Zip8 iKO WT Zip8 iKO WT Zip8 iKO 
Liver 1.57±0.12 0.36±0.03a 29.6±1.4 28.2±2.4 74.0±13.6 78.8±5.7 
Kidney 1.12±0.09 0.54±0.03a  18.8±2.7 17.7±1.5 43.3±12.2 39.7±6.6 
Brain 0.39±0.02 0.27±0.02a 15.2±0.7 15.4±1.5 16±0.9 15.1±1.2 
Heart 0.97±0.16 0.71±0.08b 16.0±2.2 15.1±0.8 72.0±8.3 72.6±3.4 
Small 
intestine 1.51±0.33 1.23±0.36 17.6±1.3 17.2±0.6 15.5±2.6 14.6±4.6 
	  
  Mn (ng/mg) Zn (ng/mg) Fe (ng/mg) 
  WT Zip8 Het WT Zip8 Het WT Zip8 Het 
Liver 1.38±0.23 0.85±0.07a 28.0±1.1 27.9±2.0 44.1±2.0 54.0±4.5 
Kidney 1.38±0.10 0.94±0.05b 17.3±0.5 16.8±1.0 40.4±6.5 38.2±5.5 
Brain 0.38±0.03 0.29±0.01b 13.3±0.1 13.7±0.6 13.3±1.3 13.3±1.4 
Heart 0.55±0.05 0.47±0.02c 14.2±1.2 15.0±0.5 55.0±7.0 70.1±9.7 
Small 
intestine 1.18±0.14 1.58±0.16b 16.3±0.5 16.1±1.1 11.9±2.2 12.0±2.8 
	  
  Mn (ng/mg) Zn (ng/mg) Fe (ng/mg) 
  WT Zip8 LSKO WT 
Zip8 
LSKO WT 
Zip8 
LSKO 
Liver 1.49±0.19 0.46±0.04a 27.6±2.9 24.6±3.0 41.4±7.3 55.0±9.5 
Kidney 1.39±0.08 0.71±0.14a 15.3±1.3 16.2±1.2 35.9±13.6 41.3±4.6 
Brain 0.32±0.01 0.21±0.02a 11.7±0.6 11.6±0.1 12.6±1.5 14.4±1.7 
Heart 0.53±0.06 0.28±0.05a 14.0±0.8 13.8±0.7 47.3±2.3 56.5±12.9 
Small 
intestine 1.05±0.04 1.08±0.13 18.1±2.0 15.2±1.0c 10.2±0.9 10.9±1.6 
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  Mn (ng/mg) Zn (ng/mg) Fe (ng/mg) 
  AAV-Null AAV-ZIP8 AAV-Null AAV-ZIP8 AAV-Null AAV-ZIP8 
Liver 1.30±0.15 2.45±0.26a 28.4±1.1 25.9±4.1 61.4±10.6 58.3±12.1 
Kidney 1.26±0.16 1.54±0.05b 16.4±1.6 16.6±1.2 34.7±5.4 37.8±13.6 
Brain 0.33±0.01 0.41±0.04b 12.1±0.7 12.1±0.9 16.4±3.3 15.1±1.5 
Heart 0.58±0.04 0.71±0.01a 15.1±0.9 17.3±5.0 63.8±9.7 65.5±10.4 
Small 
intestine 1.01±0.15 1.29±0.26c 15.7±0.9 15.3±1.0 12.9±1.9 13.6±3.4 
Table I continued. ap<0.001; bp<0.01; cp<0.05. Zip8 iKO and the control WT mice were 
males, injected with tamoxifen at 8 weeks of age, and sacrificed 5 weeks after the 
injection. N=5-6. Zip8 Het and the control WT mice were 12-14 week old male mice. 
N=4-5. Zip8 LSKO and the control WT mice were 12-14 week old male mice. N=4. AAV-
ZIP8 and the control AAV-Null mice were male, and they were injected with AAV8 at 10 
weeks of age, and sacrificed 4 weeks after injection. N=5-6.  
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Table II Mn, Zn and Fe levels in the whole blood of Slc39a8 liver-specific mouse models 
  Mn (ng/mg) Zn (ng/mg) Fe (ng/mg) 
  WT Zip8 LSKO WT Zip8 LSKO WT Zip8 LSKO 
Whole 
blood 0.04±0.02 0.01±0.00b 5.0±0.2 5.0±0.3 517.9±32.6 527.4±33.1 
  Mn (ng/mg) Zn (ng/mg) Fe (ng/mg) 
  WT AAV-ZIP8 WT AAV-ZIP8 WT AAV-ZIP8 
Whole 
blood 0.02±0.00 0.03±0.01a 5.1±0.5 5.3±0.4 536.2±28.0 515.2±14.8 
ap<0.001; bp<0.01; cp<0.05 
Zip8 LSKO and the control WT mice were 12-14 weeks old male mice. N=7 and 8. 
AAV-ZIP8 and the control AAV-Null mice were male, and they were injected with AAV8 
at 10 weeks of age and blood were obtained 4 weeks after injection. N=5-6.  
 
Table III Mn, Zn and Fe levels in the bile of Slc39a8 liver-specific mouse models 
  Mn (µM) Zn (µM) Fe (µM) 
  WT Zip8 LSKO WT Zip8 LSKO WT Zip8 LSKO 
Bile 4.4±0.6 6.8±0.4a 2.1±2.3 15.2±5.6 40.3±6.4 43.1±11.0 
  Mn (µM) Zn (µM) Fe (µM) 
  WT AAV-ZIP8 WT AAV-ZIP8 WT AAV-ZIP8 
Bile 4.7±1.2 1.1±0.3a 22.5±6.2 18.1±2.9 74.0±16.5 69.8±41.4 
ap<0.001; bp<0.01; cp<0.05. Zip8 LSKO and the control WT mice were 12-14 weeks old 
male mice. They were sacrificed after 4 hours of fasting. Each sample was pooled from 
two mice. N=4. AAV-ZIP8 and the control AAV-Null mice were male, and they were 
injected with AAV8 at 10 weeks of age and sacrificed 4 weeks after injection after 4 
hours of fasting. Each sample was pooled from two mice. N=6.  
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CHAPTER 3 
	  
SLC39A8/ZIP8 influences blood pressure by modulating arginase activity 
 
Introduction  
Hypertension, or high blood pressure, plays a major etiologic role in the development of 
cerebrovascular disease, cardiovascular disease, and renal failure (18). Multiple clinical 
trials have demonstrated that antihypertensive therapies are associated with lower rates 
of stroke, major cardiovascular events, and death from any cause (19) (23). Blood 
pressure regulation is a tightly regulated process involving multiple organ systems and 
extensive feedback pathways, including the nervous system, hormones (e.g. renin–
angiotensin system), body fluid control and regulators within the vessels (24). Identifying 
novel regulatory mechanisms of blood pressure will enhance our understanding and 
provide targets for the development of antihypertensive therapies.  
 
A genetic variant rs13107325 at the SLC39A8 genomic locus is associated with blood 
pressure in GWAS (48, 49), as well as whole blood manganese (Mn) and a variety of 
other traits. It has an 8% minor allele frequency in people of European ancestry (187) 
and is associated with lower blood pressure levels (48, 49). Importantly, it is a coding 
variant rs13107325 (Ala391Thr) producing a protein with reduced function and an eQTL 
for SLC39A8 in human liver associated with lower hepatic SLC39A8 expression (50, 52). 
This suggests that reduced SLC39A8 results in reduced blood pressure. However, the 
mechanism underlying the association of SLC39A8 with blood pressure is unknown. 
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SLC39A8 encodes a protein known as ZIP8, which is a known divalent metal ion 
transporter with ability to transport, in vitro, zinc (Zn) (63), Mn (72), iron (Fe) (82) and 
cadmium (Cd) (72). In the previous chapter, I demonstrated that hepatic SLC39A8/ZIP8 
regulates whole-body Mn homeostasis by reclaiming Mn from the bile, and that ZIP8 has 
the potential to modulate the activity of Mn-dependent enzymes. However, it remains 
unknown how ZIP8 function may mechanistically relate to blood pressure regulation. 
 
Arginase is a Mn-dependent enzyme known to influence blood pressure by regulating 
NO production (188-190), providing a plausible explanation for the association of 
SLC39A8 with blood pressure. In this study, I employed two Slc39a8 loss-of-function 
mouse models and demonstrated that Slc39a8 acts through Mn to modulate arginase 
activity, which influences blood pressure by regulating NO production.  
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Methods 
Animals. Zip8 iKO and Zip8 LSKO mice were generated as was described in Chapter 2. 
The mice were put on a high salt diet (8% NaCl) (Teklad TD.92012) for 2 weeks to 
induce hypertension (191). Blood pressure was recorded 5 weeks after tamoxifen 
injection-induced Slc39a8 deletion using an indwelling catheter and 9-22 weeks after 
tamoxifen diet-induced Slc39a8 deletion using tail cuff. Mice more than 25 g in weight 
are more likely to survive the surgery that implants telemetry probes, therefore blood 
pressure was recorded using radio telemetry 12 weeks tamoxifen injection when they 
reached the weight. 
 
Arginase activity assay. Arginase activity assay was performed as was previously 
described (192), with slight modifications. In brief, about 50 mg of liver was homogenized 
in 4x volume of PBS with protease and phosphatase inhibitor. Lysate was centrifuged at 
4ºC at 14,000 x g for 15 minutes. The supernatant was further diluted 30-fold and used 
in arginase activity assay and BCA assay. For the arginase activity assay without MnCl2 
activation, 50 µl diluted supernatant was incubated with 220 µl Glycine-NaOH buffer (pH 
9.6) and 100 µl arginine (68 mM, pH 9.6) at 37°C for 10 minutes, which a pilot 
experiment had shown to be within the linear phase of urea production. For the arginase 
activity assay with MnCl2, 50 µl diluted supernatant, either pooled or from individual 
animals, was first incubated with 20 µl MnCl2 of desired concentration and 200 µl 
Glycine-NaOH buffer (pH 9.6) at 55ºC for 10 minutes. After cooling down, 100 µl arginine 
was added and the sample was incubated at 37ºC for 10 minutes. 900 µl 
H2SO4/H3PO4/H2O (1:3:7) was added to stop the reaction. 40 µl 9% α-
isonitrosopropiophenone dissolved in ethanol was added and the sample was heated at 
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95ºC for 30 minutes to develop color. After cooling down in the dark, 200 µl of the 
sample was transferred to a 96-well plate and the color was quantified using a plate 
reader at 540 nm. Urea solutions with known concentrations (10 mM, 5 mM, 2.5 mM, 
1.25 mM, and 0.625 mM) were used to produce a standard curve. Sample urea 
production was calculated based on the standard curve and normalized to protein 
content measured by BCA assay. Arginase activity was determined by the amount of 
urea produced per µg protein in 1 minute.  
 
Urea cycle study. To induce hyperammonemia, mice were fasted for 48 hours and 
blood were obtained by retro-orbital bleed. As another approach, the mice were fed with 
a high protein diet (70% Casein, 10% CHO, 10% fat) (Teklad TD.140565) for 2-4 weeks 
and blood were obtained by decapitation using a small rodent guillotine (World Precision 
Instruments, DCAP). Upon decapitation, blood were dripped into a plate with 20 µl 
heparin. Blood obtained either way were centrifuging at 4 ºC at 2000 g for 10 minutes 
and plasma was transferred to a 1.5 mL Eppendorf tube and store at -80 ºC. Ammonia in 
the plasma was measured in the CHOP Metabolomic Core or using a commercial kit that 
converts ammonia to a product that reacts with the OxiRed probe to generate color 
(λmax = 570 nm) (BioVision K370-100). In order to examine arginine metabolism, 15N-
arginine was dissolved in saline to make a solution of 3 mg/ml which was injected into 
mice via tail vein at a dose of 150 nmol/g. 30 minutes later, the mice were sacrificed and 
blood were collected by decapitation. Plasma were transferred and stored at -80 ºC. 15N 
labeled arginine (M+4), urea (M+2), citrulline (M+2), ornithine (M+2) were measured in 
the CHOP Metabolomic Core, as has been previously described (193). Amino acid 
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profiling of plasma obtained by decapitation was also performed in the CHOP 
Metabolomics Core.  
 
NO analysis. NOx (primarily nitrate, nitrite, NO-metal complexes, and low-molecular- 
weight and protein cysteine-NO adducts) levels were determined using the method 
described by Lundberg and Govoni. In brief, plasma samples were deproteinized by 
passing through a 30 kD cut off filter (AmiconUltra-0.5 Centrifugal Filter Unit, EMD 
Millipore). The filtrate was diluted 4 times using de-ionized water and 10 µl was injected 
into an ice-water-cooled reaction chamber containing vanadium (III)/hydrochloric acid 
solution heated to 95°C. The NO generated from the reduction of NOx was quantified by 
its gas phase chemiluminescence reaction with ozone (Nitric Oxide Analyzer; Sievers 
Instruments, Boulder, CO). Signal peaks (mV) were manually integrated to obtain areas, 
which were used to quantify NOx concentration. A standard curve was constructed by 
injecting known concentrations of nitrate and plotting area against nitrate content. 
To measure endothelial NO production of aorta, thoracic aorta was isolated and pinned 
down in Krebs-Henseleit buffer (Sigma K3753). NO release from the endothelial surface 
was measured with a NO-selective microelectrode coupled with an Apollo 4000 Free 
Radical Analyzer (WPI). Buffer temperature was maintained at 37 °C throughout the 
experiment. NO values were normalized to the wet weight of the tissue. 
 
Hemodynamic analysis. Hemodynamic analysis was performed as was previously 
described (194). Mice were anesthetized with Avertin (200-250 mg/kg IP) and placed on 
a heating pad to maintain body temperature at 37°C. The right carotid artery was 
exposed and a catheter was inserted into the carotid artery and advanced down the 
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ascending aorta and past the aortic valve into the left ventricle (LV). After 3 minutes of 
stabilization, LV pressure and other derived cardiac function parameters (dp/dt/max, 
dp/dt/min, tau) were measured three times by averaging 10 seconds recordings. Then 
the catheter was retracted from LV and arterial pressure was measured at the ascending 
aorta site. 
 
Tail cuff blood pressure measurement. Systolic blood pressure (SBP) was 
determined by the Visitech tail cuff plethysmography system as was previously 
described (195). The mice were mounted on a platform maintained at 37 °C and the tails 
were inserted through a tail-cuff attached to the pressure monitoring system. For each 
day, 5 preliminary cycles and 15 measurement cycles were recorded. The mean of the 
measurement cycles was accepted as the SBP of the day. The mice were acclimated for 
3 days and blood pressure was monitored for 5 days at the same time of the day. The 
mean of the SBP of the 5 days was accepted as the SBP of the mouse. 
 
Radiotelemetry. Continuous 24-hour systolic, diastolic, pulse pressure, mean pressure, 
heart rate, and activity were monitored in unrestricted animals with the Dataquest IV 
system (Data Sciences) as was described previously (191). Briefly, male mice (4-5 
months old, >25 g in weight) were anesthetized with ketamine [100 mg/kg, 
intraperitoneally (ip)] and xylazine (5 mg/kg, ip) and were subjected to surgery under 
strict sterile conditions. A horizontal incision was made on the back, and the telemetry 
probe (TA11-PA20; Transoma Medical Inc., Data Sciences International) was inserted. 
The tip of the transmitter catheter was inserted into the common carotid lumen and 
advanced until the catheter notch reached the level of the carotid bifurcation. After 
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surgery, the mice were allowed to recover for 5 days, after which the telemetry probes 
were turned on to begin data acquisition. The cages with the animals in them were 
placed on a receiver plate, and the signals were collected with the Dataquest LabPRO 
acquisition system (version IV; Transoma Medical Inc., Data Sciences International) for 3 
consecutive days. Ten-second waveforms of systolic arterial pressure, diastolic arterial 
pressure pulse pressure, mean arterial pressure, heart rate, and locomotor activity were 
sampled every 5 minutes during the monitoring periods, hourly averages were exported, 
and 3-day averages of blood pressure at each hour of the day were calculated. The 
nighttime (7 pm-6 am) and daytime (7 am-6 pm) blood pressure were also calculated. 
For animals treated with high salt diet, blood pressure was recorded before and after the 
diet.  
 
Statistical analyses. Comparisons of two samples were performed using two-tailed 
Studentʼs t-test. Correlation analyses were performed using Pearson test. Meta-analyses 
were performed using inverse variance based analytical strategy and under equal 
variance assumption (196). A p-value of less than 0.05 was considered significant. 
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Results 
Zip8 acts through Mn to quantitatively modulate arginase activity.  
Arginase is a Mn-dependent enzyme that binds Mn in the catalytic site and requires Mn 
for catalytic activity. Given that Slc39a8 quantitatively modulates Mn levels, as was 
shown in the previous chapter, I examined arginase activity in the liver of Slc39a8 mouse 
models. Slc39a8 liver-specific knockout (Zip8 LSKO) mice had a significant decrease in 
hepatic arginase activity, which was rescued by liver-specific over-expression of human 
ZIP8 using AAV (Figure 8A). Hepatic arginase activity was also decreased in female 
Zip8 LSKO mice (-60%, p<0.001), as well as in male inducible global knockout (Zip8 
iKO) and heterozygous (Zip8 Het) mice (-47%, p<0.001 and -25%, p=0.009 
respectively). Conversely, liver-specific over-expression (AAV-ZIP8) mice, which had 
increased hepatic Mn, had increased hepatic arginase activity (+67%, p<0.001) (Figure 
8B). In both Zip8 LSKO and AAV-ZIP8 mice, arginase protein levels were not changed, 
shown by western blot analysis (Figure 8C), indicating a change in the specific activity of 
the protein.   
 
Pre-incubation of pooled WT and Zip8 LSKO liver lysate ex vivo with increasing 
concentrations of MnCl2 revealed that the addition of Mn progressively increased 
arginase activity until reaching a plateau (Figure 8D and E). Examination of the relative 
arginase activity under each MnCl2 concentration revealed that hepatic arginase activity 
in the Zip8 LSKO mice was lower than in WT mice without added Mn but was restored to 
the same level as WT mice at a MnCl2 concentration of 250 µM or higher (Figure 8F). 
Similar experiments with liver lysate from individual animals confirmed that 250 µM 
MnCl2 increased hepatic arginase activity of both WT and Zip8 LSKO mice and 
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eliminated their difference (Figure 8G). Thus, Mn added ex vivo rescues the defective 
arginase activity in livers from Zip8 LSKO mice. 
 
Correlation analyses using arginase data of all four mouse models generated in this 
Chapter and Mn data of all fours mouse models generated in the previous chapter 
revealed a very strong and significant linear correlation between hepatic Mn levels and 
hepatic arginase activity (r=0.9558, p<0.001) (Figure 8H).  Zip8 LSKO mice, which had 
decreased Mn in the kidney (-40%, p=0.001) (Figure 8I) consistent with the previous 
experiment shown in Figure 2, also had significantly decreased arginase activity in the 
kidney (-20%, p=0.002) (Figure 8J).  Furthermore, kidney arginase activity linearly 
correlated with kidney Mn levels (r=0.8570, p=0.0015) (Figure 8K). Thus, tissue Mn 
content is a quantitative regulator of tissue arginase activity over a wide range of Mn 
concentrations. Taken together, these results demonstrate that hepatic Zip8 acts to 
maintain tissue Mn homeostasis, which in turn modulates arginase activity, not only in 
the liver but in extrahepatic tissues as well.  
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Figure 8. Zip8 acts through Mn to quantitatively modulate arginase activity (A) 
Arginase activity of the liver of 8-10 weeks old male Slc39a8fl/fl mice (WT) injected with 
AAV-Null and Slc39a8fl/fl; Alb-Cre mice (Zip8 LSKO) injected with AAV-Null or AAV-ZIP8 
and sacrificed 4 weeks after the injection. n=7, 4, and 4. (B) Arginase activity of the liver 
of 10 weeks old male B6 mice injected with AAV-Null or AAV-ZIP8 and sacrificed 4 
weeks after the injection. n=5 and 6. (C) Western blot analysis of arginase protein in the 
liver lysate of (A) and (B). (D-E) Arginase activity of 10 weeks old male Slc39a8fl/fl and 
Slc39a8fl/fl; Alb-Cre mouse liver after pre-incubation with increasing concentrations of 
MnCl2. Lysate from three mice of the same genotype were pooled and three technical 
repeats were performed. (F) Arginase activity of D and E normalized to the average of 
the Slc39a8fl/fl under each MnCl2 concentration. (G) Arginase activity of individual 10-
week-old male Slc39a8fl/fl and Slc39a8fl/fl; Alb-Cre mouse liver with or without pre-
incubation with 250 µM MnCl2. n=6 and 7. (H) Correlation analysis of hepatic Mn and 
arginase activity in all four mouse models. Mn and arginase activity were normalized to 
the average of the control groups. n=41. (I). ICP-OES analysis of kidney Mn in 10-12 
weeks old male Slc39a8fl/fl and Slc39a8fl/fl; Alb-Cre mice. n=5. ICP-OES results were 
normalized to wet tissue weight. Mn levels were normalized to the average of the control 
group. (J) Arginase activity in the kidney of mice from (I). n=5. (K) Correlation analysis of 
kidney Mn and arginase activity in mice from (I) and (J). n=10. Mn and arginase activity 
were normalized to the average of the control group. All data are shown as the mean ± 
SD. Comparisons between two groups were performed using Studentʼs t-test. Multiple 
comparisons in Figure 4A were performed using one-way ANOVA and Tukeyʼs multiple 
comparison test, and multiple comparisons in Figure 4G were performed using two-way 
ANOVA and Bonferroni post-test. ***p ≤ 0.001, **p ≤ 0.01, *p ≤0.05. Correlation analyses 
were performed using Pearson test. 
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Slc39a8 liver-specific deletion does not result in urea cycle defects. 
 Arginase mediates the last step of the urea cycle, the major pathway for the 
detoxification of ammonia in mammals (197). Arginase mutations in human and arginase 
deletions in mice have resulted in hyperammonemia. Therefore, I challenged WT and 
Zip8 LSKO mice with 48-hour-fasting or a high protein diet, both of which have been 
used to bring out a hyperammonemia phenotype in mice (198, 199). Zip8 LSKO mice 
had normal plasma ammonia level on chow diet before and after 48 hours of fasting 
(Figure 9A). Plasma ammonia levels were also normal after the mice were put on the 
high protein diet for 2 and 4 weeks (Figure 9B and C). Even though different methods 
were used in these experiments to measure ammonia, there was a high correlation 
between ammonia measurements obtained using these two methods (r=0.9266, 
p=0.0009). Amino acid profiling of pooled plasma samples collected after the mice were 
treated with the high protein diet for 2 weeks did not reveal significant differences in 
amino acid levels between WT and Zip8 LSKO mice (Figure 9D). In order to examine 
more specifically the metabolism of arginine, I injected WT and Zip8 LSKO mice with 
15N-arginine. Prior to that, I performed a pilot experiment in B6 mice, which showed that 
30 minutes post injection is the optimal time-point to terminate the experiment as 
arginine and arginine metabolite levels were detectable and stable (Fig. 9E). Zip8 LSKO 
mice had normal levels of 15N-arginine and 15N-arginine metabolites, including 15N-
ornithine and 15N-citrulline (Fig. 9F-H). These observations combined suggest that Zip8 
LSKO mice did not develop urea cycle defects.  
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Figure 9. Slc39a8 liver-specific deletion does not result in urea cycle defects (A) 
Plasma ammonia analysis using an OxiRed based assay of 12-14 weeks old male 
Slc39a8fl/fl and Slc39a8fl/fl; Alb-Cre mice on chow diet before and after 48 hours of 
fasting. N=6. (B-C) Plasma ammonia analysis using a NADPH based assay of 12-14 
weeks old female Slc39a8fl/fl and Slc39a8fl/fl; Alb-Cre mice 2 and 4 weeks after a high 
protein diet. N=5. (D) Amino acid analysis of pooled samples of (B). N=1. (E) 15N-
arginine, 15N-ornithine and 15N-citrulline analysis of 14 weeks old male WT mice injected 
with 15N-arginine and sacrificed 15, 30, and 60 minutes after the injection. (N=1). (F-H) 
15N-arginine, 15N-ornithine and 15N-citrulline analyses of 12-14 weeks old male Slc39a8fl/fl 
and Slc39a8fl/fl; Alb-Cre mice injected with 15N-arginine and sacrificed 30 minutes after 
the injection. N=4. All data are shown as the mean ± SD.  
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Slc39a8 deletion results in increased NO and decreased blood pressure.  
Arginine is a major source of nitric oxide production, and arginase, by metabolizing 
arginine, reduces the bioavailability of arginine for NO production (200). Arginase 
inhibition has been shown to decrease blood pressure by increasing NO production and 
improving NO-dependent vasodilation (188-190). To determine whether decreased 
arginase activity as a result of Slc39a8 deletion would result in increased NO production, 
I measured the NO metabolite (NOx) in plasma of WT and Zip8 LSKO mice. These mice, 
which had decreased arginase activity in the liver and kidney, had increased plasma 
NOx (+31%, p=0.012), indicating increased NO bioavailability (Figure 10A). In support of 
this, endothelial NO production analysis using thoracic aortic rings suggested that Zip8 
LSKO had increased NO production (41%, p=0.383) (Figure 10B). Moreover, 
hemodynamic analysis using an indwelling catheter revealed that Zip8 iKO mice had 
decreased systolic arterial pressure (SAP) (-6.9mmHg, p=0.031) (Figure 10C), likely as 
a result of increased NO. Left-ventricle end systolic pressure (LV ESP) was also 
decreased in Zip8 iKO (b=-4.17mmHg, p=0.026) (Figure 10D), which is another indicator 
of increased NO (201, 202). The experiment was repeated 3 more times and a meta-
analysis of all the experiments was performed, confirming that Zip8 iKO mice had 
decreased SAP (-4.44 mmHg, p=0.018) and LV ESP (-4.17 mmHg, p=0.026). The effect 
of Slc39a8 deletion on blood pressure was further confirmed by another sets of 
experiments where Slc39a8 deletion was induced using a tamoxifen citrate diet and 
blood pressure was measured using tail cuff in both female and male mice. A meta-
analysis of these experiments showed that Zip8 iKO mice had decreased systolic blood 
pressure (SBP) (- 3.6 mmHg, p<0.001). These findings are directionally consistent with 
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the observation in humans that the genetic variant that decreases hepatic SLC39A8 
expression is associated with decreased blood pressure. 
 
Figure 10. Slc39a8 deletion results in increased NO and decreased blood 
pressure (A) Plasma NOx analysis of 12-16 weeks old male Slc39a8fl/fl and Slc39a8fl/fl; 
Alb-Cre mice. N=10. (B) NO production from thoracic aorta of 12-14 weeks old female 
Slc39a8fl/fl and Slc39a8fl/fl; Alb-Cre mice. N=6. (C-D) Systolic arterial pressure (SAP) and 
left ventricle pressure (LV ESP) measured using an indwelling catheter of female 
Slc39a8fl/fl and Slc39a8fl/fl; UBC-Cre/ERT2 mice injected with tamoxifen at 6 weeks of age 
and sacrificed 5 weeks after the injection. All data are shown as the mean ± SD. 
Comparisons between two groups were performed using Studentʼs t-test. *p≤0.05.  
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Slc39a8 deletion protects mice against high-salt-induced hypertension. 
Arginase protein level and activity have been shown to be increased after high-salt 
treatment and is believed to contribute to high-salt-induced endothelial dysfunction and 
hypertension (203, 204). Therefore, I treated Zip8 iKO mice with a high-salt diet to 
determine if they would be protected against high-salt-induced hypertension. 
Radiotelemetry was used to record blood pressure before and after the dietary 
treatment, which enabled continuously monitoring of blood pressure under the 
physiological states of the mice. At baseline, WT and Zip8 iKO mice had comparable 
systolic blood pressure (SBP) and diastolic blood pressure (DBP) levels and patterns 
throughout 24 hours of the day (Figure 11A and C). Average nighttime and daytime SBP 
and DBP levels were also not different between the two groups (Figure 11B and D). 
Interestingly, after the dietary treatment, Zip8 iKO mice had lower SBP and DBP through 
24 hours of the day compared with the WT mice (Figure 11E and G). Average nighttime 
and daytime SBP and DBP were also trended toward being lower (nighttime SBP: -40.0 
mmHg, p=0.07; daytime SBP: -30.0 mmHg, p=0.05; nighttime DBP: -34.1 mmHg, 
p=0.07; daytime DBP: -26.0 mmHg, p=0.10) (Figure 11F and H). Intriguingly, the high-
salt diet resulted in increased SBP in WT mice, but decreased SBP in Zip8 iKO mice 
(Nighttime WT vs. Zip8 iKO: +11.5% vs. -35.4%, p=0.023; daytime WT vs. Zip8 iKO: 
+20.7% vs. -30.8%, p=0.023) (Figure 11I). Similar observations were made with DBP 
(nighttime WT vs. Zip8 iKO: +23.7% vs. -33.6%, p=0.015; daytime WT vs. Zip8 iKO: 
+33.3% vs. -22.6%, p=0.097) (Figure 11J). These results suggest that Slc39a8 deletion 
is protective against salt-induced hypertension. 
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Figure 11. Slc39a8 deletion protects mice against high-salt-induced hypertension 
(A-D) Radio telemetry results of hour-to-hour and average nighttime (7 pm-6 am) and 
daytime (7 am-6 pm) systolic blood pressure (SBP) and diastolic blood pressure (DBP) 
of male Slc39a8fl/fl and Slc39a8fl/fl; UBC-Cre/ERT2 mice injected with tamoxifen at 6 
weeks of age and sacrificed 12 weeks after the injection. N=5. (E-H) Radio telemetry 
results of hour-to-hour and average nighttime (7 pm-6 am) and daytime (7 am-6 pm) 
SBP and DBP of mice from A-D after 2 weeks of high-salt dietary treatment. N=5. (I-J) 
Percentage changes from baseline (before high salt diet) of SBP and DBP of mice from 
(A-H). N=5. All data are shown as the mean ± SD. Comparisons between two groups 
were performed using Studentʼs t-test.  
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SLC39A8 loss-of-function variant is associated with increased NOx in human. 
The variant in SLC39A8 associated with pleiotropic traits including blood pressure is a 
coding variant rs13107325 (Ala391Thr). This coding variant has been reported to have 
reduced activity, and in addition the minor allele is associated with lower hepatic 
SLC39A8 expression (50, 52). To determine whether genetically reduced SLC39A8 
activity has an effect on NO production in humans, I examined NOx in the plasma of 
rs13107325 A391T homozygotes and matched major allele A391 homozygotes. A391T 
homozygotes had increased NOx compared with major allele homozygotes (Figure 12), 
suggesting that SLC39A8 loss-of-function results in increased NO production in humans, 
consistent with the association of A391T with decreased blood pressure.  
 
 
Figure 12. SLC39A8 loss-of-function variant is associated with increased NOx in 
human NOx analysis in the plasma of male, white, 60-65 years old rs13107325 major 
and minor allele homozygotes. N=12. All data are shown as the mean ± SD. 
Comparisons between two groups were performed using Studentʼs t-test. *p≤0.05. 
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Discussion 
Spurred by the observation that a coding variant in the SLC39A8 gene is associated with 
blood pressure and my previous observation in mice that hepatic Slc39a8 is a 
quantitative regulator of whole-body Mn levels, I utilized two Slc39a8 loss-of-function 
mouse models to test the hypothesis that the modulation of Mn-dependent enzyme 
activity may underlie the association of SLC39A8 with blood pressure. I discovered in 
mice that Slc39a8 deletion decreased the activity of the Mn-dependent enzyme 
arginase, increased NO production, decreased blood pressure, and protected mice 
against high-salt diet-induced hypertension. Furthermore, I showed that homozygotes for 
the human coding variant A391T associated with decreased SLC39A8 expression and 
function have evidence for increased NO. Arginase restricts the availability of the NO-
precursor arginine (200), and arginase inhibition has been shown to increase NO 
bioavailability, improve endothelial dysfunction, and reduce blood pressure (188-190). 
Therefore, these results provide a plausible and directionally consistent explanation for 
the association of A391T at the SLC39A8/ZIP8 locus with blood pressure where 
decreased SLC39A8 acts through Mn to decrease arginase activity, which results in 
increased NO production and decreased blood pressure. 
 
One key finding of my study is that ZIP8 is a key regulator of tissue arginase activity 
through its regulation of tissue Mn levels. Arginase is known to be a Mn metalloenzyme, 
but the role of Mn in quantitatively regulating arginase activity had not been described in 
vivo. My results indicate that Mn quantitatively modulates arginase activity over a wide 
range both below and above normal physiological levels. Importantly, hepatic Slc39a8 
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expression, by regulating whole-body tissue Mn levels, regulates arginase activity not 
only in the liver but in other tissues as well.  
 
One interesting observation in my study of Mn-dependent enzymes is the differential 
regulation of enzymatic activity by Mn. Slc39a8 loss-of-function mice had dramatic 
decrease in arginase activity but normal MnSOD activity, as was shown in the previous 
chapter. Unlike arginase, Mn binding to MnSOD is considered irreversible, because the 
binding is resistant to metal chelation and that dissociation only occurs under denaturing 
conditions (205). Changes in the metalation state of MnSOD require a large activation 
barrier (206, 207). In fact, this prevents the use of direct titration to measure Mn binding 
affinity of MnSOD. Using an indirect calorimetric method, It was shown that the binding 
constant for Mn with MnSOD is 0.032 µM (206). In contrast, Mn binding to arginase is 
reversible and arginase activity was decreased by 50% due to Mn dissociation by metal 
chelation. The binding constant for chelation-resistant Mn is 0.7 µM and that for the 
reversibly removable Mn is 20 mM (208). Therefore, the difference in Mn binding affinity 
and the large activation barrier required for Mn dissociation from MnSOD may explain 
why I observed decreased arginase activity, but not MnSOD, in Slc39a8 loss-of-function 
mice (209). As to β-1, 4-galactosyltransferase, its activity is also chelatable, and it has 
one site that binds Mn with a Km value of 0.4 µM and another that binds manganese with 
a Km value of 440 µM. The N-glycan profile of Slc39a8 loss-of-function mouse models, 
which was shown in the previous chapter, strongly suggests β-1, 4-galactosyltransferase 
activity is decreased by Slc39a8 deletion in vivo. The enzymatic activity was not 
detectable ex vivo without MnCl2, probably because the enzyme was not able to retain 
Mn during the sample preparation process. Addition of MnCl2 dramatically increased the 
73 
enzymatic activity but revealed no difference between WT and Zip8 iKO, likely because it 
fully restored the decreased enzymatic activity in the Zip8 iKO sample, supporting the 
notion that the enzymatic difference is attributable to the difference in Mn levels.  
Arginase mediates the last step of the urea cycle, the major pathway for the 
detoxification of ammonia in mammals. Deficiency of liver arginase (arginase I) causes 
hyperargininemia (OMIM 207800), a disorder characterized by progressive mental 
impairment, growth retardation, and spasticity punctuated by infrequent fatal episodes of 
hyperammonemia (210). Arginase I knockout (211) and inducible knockout mice (212) 
had severe hyperammonemia and died within 2 weeks after arginase deletion. It is worth 
noting that arginase I heterozygous mice are phenotypically normal and had normal 
levels of plasma ammonia and amino acids, despite around 50% decrease of arginase 
activity in the liver (212). Zip8 LSKO mice retain 30% of normal arginase activity, which 
may explain why they did not develop urea cycle defects. 
 
Another key finding of my study is that by regulating arginase activity, ZIP8 influences 
NO bioavailability and blood pressure. Arginase activity impairs NO production by 
restricting the substrate arginine (200). I discovered in mice that Slc39a8 deletion led to 
decreased arginase activity in the liver and kidney, increased NOx in the plasma, and 
decreased blood pressure. In addition, I discovered in human that the coding variant 
associated with decreased hepatic SLC39A8 is associated with increased plasma NOx 
in clinical samples. Increased plasma NOx has been used as an indicator of decreased 
blood pressure in animals and humans (213, 214), and arginase inhibition has been 
shown to increase NO bioavailability, improve endothelial dysfunction, and ultimately 
reduce blood pressure (188-190). It is important to note that the coding variant 
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associated with decreased hepatic SLC39A8 expression and increased NOx is 
associated with decreased blood pressure in human, suggesting that the regulation of 
Mn homeostasis by ZIP8 and the subsequent regulation of arginase activity and NO may 
underlie the association of the SLC39A8 locus with blood pressure.  
 
It is worth noting that increased NOx in the plasma of SLC39A8 loss-of-function mice 
and humans may be a result of decreased arginase activity in endothelial cells, which 
resulted in increased availability of arginine for NO production by eNOS. It may also be 
contributed by decreased arginase activity in the liver and other organs, which resulted 
in increased flux of arginine to endothelial cells for NO production. Therefore, over-
expressing arginase in the liver of Zip8 LSKO may be one way to prove the causality 
between decreased arginase activity and increased NO production.  
 
Finally, I demonstrated that decreased arginase activity as a result of Slc39a8 deletion 
protected mice against high-salt induced hypertension. Elevated arginase activity has 
been implicated in hypertension induced by high salt diet, deoxycorticosterone acetate-
salt, aging, angiotensin II, and aortic coarctation, and arginase inhibition has been 
shown to increase vasoreactivity and decrease blood pressure under these conditions 
(189, 200, 203, 204, 215). The finding that Zip8 iKO mice had lower blood pressure 
compared with WT under high-salt diet treatment suggests that arginase may underlie 
the association of SLC39A8 with blood pressure in GWAS especially among subjects 
that are exposed high dietary salt. In addition, the finding that high-salt diet resulted in 
hypertension in WT but not Zip8 iKO mice suggests that SLC39A8 may be a therapeutic 
target for inhibition in the treatment of hypertension induced by high dietary salt. Zip8 
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iKO mice did not show decreased blood pressure than WT group at baseline, likely 
because of the long time between gene deletion and blood pressure measurement (12 
weeks), which may have allowed recovery of Slc39a8 deletion in certain organs and 
tissues relevant to blood pressure regulation. 
 
In literature, two hypotheses have been proposed to explain the association of SLC39A8 
with blood pressure. One is that SLC39A8 mediates Cd transport to increase blood 
pressure, given that the minor allele of rs13107325 was shown to impair Cd transport by 
ZIP8 (59), that plasma and renal Cd levels have been associated with hypertension and 
hypertension-related death in human (154, 216), and that the causal relationship 
between Cd exposure, especially chronic low-dose Cd exposure, and hypertension has 
been proven in multiple animal models (153, 217, 218). I attempted to examine whether 
Slc39a8 deletion would protect mice against Cd-induced hypertension. However, the 
Slc39a8 mouse models and the control mice are on B6 background, which has been 
shown to be resistant to Cd accumulation in the vasculature (83), and I have not been 
able to induce consistent hypertension in the control group with CdCl2 H2O treatment 
(400 mg/L for 24 weeks). It has also been proposed that SLC39A8 acts through N-
terminal pro B-type natriuretic peptide (NT-proBNP) to regulate blood pressure, given 
that the minor allele of rs13107325 was found to be associated with increased NT-
proBNP in GWAS, and that genetic variants associated with lower plasma NT-proBNP 
levels are associated with higher blood pressure in GWAS (219, 220). I measured NT-
proBNP levels in the plasma of male and female Zip8 LSKO and Zip8 iKO mice as well 
as corresponding controls. There was no difference in female Slc39a8 loss-of-function 
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mice and a trend of increase in male Slc39a8 loss-of-function mice compared with 
corresponding controls.  
 
In summary, this study provides a plausible and directionally consistent explanation for 
the association of the genetic variant at the SLC39A8/ZIP8 locus with blood pressure 
(Figure 13). Furthermore, it implicates Mn as a novel regulator of blood pressure through 
regulating arginase activity and NO production and suggests that SLC39A8 may be a 
therapeutic target for inhibition in the treatment of hypertension.  
 
 
Figure 13. Slc39a8/Zip8 influences blood pressure by modulating arginase activity 
Slc39a8/Zip8 reclaims Mn from bile to maintain whole-body Mn and the activity of Mn-
dependent enzymes including arginase. Under Slc39a8 loss-of-function, increased 
biliary secretion leads to systemic Mn deficiency. The subsequent decrease in arginase 
activity results in increased availability of arginine for NO production, increased NO, and 
decreased blood pressure.  
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CHAPTER 4 
 
SLC39A8/ZIP8 acts through Zn to influence HDL-C  
 
Introduction  
Raising high-density lipoprotein cholesterol (HDL-C) levels may lower the risk for 
cardiovascular diseases (CVD) (221, 222), the leading cause of morbidity and mortality 
in the US and worldwide (223). HDL takes up cholesterol from peripheral tissues, such 
as macrophages, and returns it to the liver for excretion, a process termed reverse 
cholesterol transport (RCT) (224). There is evidence that RCT protects against CVD 
(225), and it has also been proposed that HDL can also protect against CVD via anti-
inflammatory, antioxidant, and antithrombotic effects (224). The biosynthesis of HDL-C 
involves the synthesis and secretion of its major protein components, apoA-I and apoA-
II, in the liver and small intestine, followed by the acquisition of lipids (phospholipids and 
cholesterol) and the assembly and generation of the mature HDL particle. The 
catabolism of HDL-C involves the excretion of cholesterol from the liver and the 
degradation of lipid-poor apoA-I by the kidney (224). Both are complexes processes that 
involve multiple players.  
 
Blood lipid levels are common complex traits affected by multiple genetic and 
environmental factors, and genome wide association studies have identified novel 
regulators of HDL-C. Common genetic variants at a genomic locus including the 
SLC39A8 gene are genome-wide significantly associated with HDL-C (50, 51), and the 
lead variant is associated with lower HDL-C. As was mentioned in the previous chapters, 
the lead variant has been shown to decrease hepatic SLC39A8 level and impair the 
function ZIP8, the protein encoded by SLC39A8. These observations suggest that 
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SLC39A8 may play a role in HDL-C regulation, and that decreased SLC39A8 expression 
or ZIP8 function may lead to decreased HDL-C, however the mechanism is unknown. 
 
SLC39A8/ZIP8 was first discovered as a Zn transporter based on homology with the ZIP 
family of metal ion transporters (63). In vitro, Zip8 has promoted cellular Zn uptake when 
over-expressed in HEK293T cells (82), CHO cells (63), and Xenopus oocyte (66). In 
vivo, Zip8 hypomorph (neo/neo) newborns exhibited diminished zinc levels in several 
tissues (76), while elevated Zip8 was observed during host defense (80) and 
osteoarthritis (81) to promote cellular Zn uptake. However, it remains unclear how, or 
indeed if Zn may mechanistically relate to the association of SLC39A8 with HDL-C. 
 
Zn is an essential trace nutrient required for the structure and function of numerous 
enzymes and transcription factors (84). Human and mouse studies on the effect of Zn 
deficiency and Zn supplementation on HDL-C levels have generated mixed results (226), 
but Zn deficiency has been shown to decrease HDL-C levels in rat (227), and serum Zn 
has been shown to positively correlate with HDL-C in human (228). ApoA-I is the main 
protein component of HDL-C. Interestingly, Zn deficiency has been shown to decrease 
ApoA-I in the liver and plasma of rats and hamsters (229). In addition, Zn deficiency was 
found to decrease apoA-I promoter activity in hepG2 cells, concomitant with a decrease 
in the level of two Zn-dependent transcription factors required for ApoA-I expression 
(230).  
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In this study, utilizing several Slc39a8 gain and loss-of-function mouse models, I 
discovered that Slc39a8 is a HDL-C regulator and that Zn may be involved in the 
regulation. The mechanism in which Zn may influence HDL-C requires further study.   
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Methods 
Animals. Zip8 iKO, Zip8 LSKO, and AAV-ZIP8 mice were generated as was described 
in Chapter 2. Acute liver-specific Slc39a8 deletion was achieved by intraperitoneally 
injecting Slc39a8fl/fl mice with AAV8 carrying a vector that expresses Cre under the 
control of the liver specific TBG promoter. The mice were put on a western diet 
(Research Diets, D12079Bi) for 3-6 weeks to raise plasma lipid levels. To induce Zn 
deficiency, the mice were fed with a Zn deficient diet (Zn: 1 ppm, Teklad, TD85419) 
(231), and A Zn adequate diet (Zn: 50 ppm, Teklad, TD85420) was used as control. 
Plasma Zn levels were monitored using the QuantiChrom™ Zinc Assay Kit (BioAssay 
Systems, DIZN-250) which utilizes a chromogen that forms a colored complex 
specifically with Zn. 
 
Plasma lipid and ALT analysis. Blood was collected by retro-orbital bleeding after 4 
hours of fasting and plasma was isolated by centrifugation of the blood at 10000 rpm for 
10 minutes. Plasma lipids and ALT in individual samples were analyzed by analytical 
chemistry (Cobas Mira Autoanalyzer; Roche Diagnostic Systems). Plasma lipids in 
pooled samples (150 µl) were analyzed by fast protein liquid chromatography (FPLC). 
Cholesterol plate assays were performed on FPLC fractions using Infinity Cholesterol 
Reagents. 
 
Metal ion measurement. Hepatic Zn was measured using ICP-OES as was described 
in Chapter 2.  
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Glucose tolerance test. After overnight fasting, baseline blood glucose levels of the 
mice were recorded using One Touch glucose meter and test strips. The mice were then 
injected intraperitoneally with 20% w/v glucose solution at a dose of 10 µl/g, and blood 
glucose levels were recorded 15, 30, 60, 90, and 120 minutes after the injection. 
  
qPCR. cDNA was prepared as was described in Chapter 2. SYBR primers used for 
qPCR were ApoA-I F: 5ʼ-TGGGCTACATCAGGCTTTGAG-3ʼ; ApoA-I R 5ʼ-
CTCTCCTACAACCTTCCCCTC-3ʼ; Glut4 F: 5ʼ-GGCTACGGCTACTATCGCAC-3ʼ; Glut4 
R:	  5’-­‐AGGAGGGCATGACAAAGGAGA-3ʼ. 
 
Statistical analyses. Comparisons between two groups of mice were performed using 
Studentʼs t-test. Correlation analyses were performed using Pearson test. p<0.05 was 
considered significant.  
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Results 
Slc39a8 liver-specific over-expression in mice results in increased HDL-C. 
The liver plays a central role in HDL-C metabolism and Apo-AI synthesis. As the first 
step of studying the role of Zip8 in HDL-C metabolism, I over-expressed human ZIP8 in 
the liver of B6 mice by injecting them with AAV8 carrying a vector that expresses ZIP8 
under the control of the liver-specific TBG promoter (AAV-ZIP8). Mice injected with 
AAV8 carrying an empty vector were used as control (AAV-Null). AAV-ZIP8 mice had 
increased HDL-C, but only at a high dose of virus of 1x1012 GC/mouse and only at 4 
weeks after injection (+12.2%, p=0.023) (Figure 14A and B). The increase in HDL-C is 
consistent with the observation in GWAS that the minor allele of rs13107325 is 
associated with decreased hepatic SLC39A8 and decreased HDL-C. Hepatic ApoA-I 
transcription levels were not different between AAV-Null and AAV-ZIP8 mice at week 6 
(Figure 14C).  
 
 
Figure 14. Slc39a8 liver-specific over-expression results in increased HDL-C (A) 
HDL-C of adult 10 week old male B6 mice 2, 4, and 6 weeks after injection of AAV-Null 
at a dose of 1 x1012 GC/mouse or AAV-ZIP8 at a dose of 1 x1011 or 1x1012 GC/mouse. 
N=6. (B) HDL-C at the week-4 time point of (A). (C) qRT-PCR of hepatic Apo-AI at the 
week-6 time point of (A). All data are shown as the mean ± SD. Comparisons between 
two groups were performed using Studentʼs t-test. *p≤0.05.  
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Global Slc39a8 deletion does not alter HDL-C levels. 
To study the physiological role of Zip8 in HDL-C metabolism, I characterized the HDL-C 
phenotype of two Slc39a8 global loss-of-function mouse models: heterozygous mice 
(Zip8 Het) and tamoxifen-induced global knockout mice (Zip8 iKO). Neither Zip8 Het nor 
Zip8 iKO mice had a HDL-C phenotype on chow or western diet, compared with 
corresponding controls (Figure 15A-C). Given the association of SLC39A8 with BMI, 
body weights of Zip8 iKO and the control were recorded but no difference was observed 
between groups (Figure 15D).  
 
 
Figure 15. Global Slc39a8 deletion does not alter HDL-C levels (A) HDL-C of 12-16 
weeks old male WT and Zip8 Het mice on chow diet. N=7. (B) HDL-C of 12-16 weeks old 
male WT and Zip8 Het mice on western diet for 4 weeks. N=4. (C) HDL-C of male 
Slc39a8fl/fl (WT) and Slc39a8fl/fl; UBC-Cre/ERT2 (Zip8 iKO) mice injected with tamoxifen 
at 8 weeks of age and bled 4, 7, 10, 13, and 16 weeks after tamoxifen injection. The 
mice were on chow diet until week 13 when western diet started, as was indicated by the 
arrow. N=7. (D) Body weight of mice from (C). N=7. All data are shown as the mean ± 
SD. 
 
 
84 
Acute Slc39a8 liver-specific deletion leads to decreased HDL-C contributed by 
decreased Zn and increased ALT. 
To examine the effect of liver-specific Slc39a8 deletion on HDL-C metabolism, Slc39a8fl/fl 
mice were injected with AAV8 carrying a vector that expresses Cre under the control of 
the liver specific TBG promoter to achieve acute hepatocyte-specific Slc39a8 deletion in 
the adult stage (AAV-Cre). Slc39a8fl/fl mice injected with AAV8 carrying an empty vector 
were used as control (AAV-Null). AAV-Cre mice had decreased HDL-C at 4, 6, and 8 
weeks after injection (Figure 16A), accompanied by elevated plasma ALT. At 14.5 weeks 
after the injection, ALT was significant elevated (Figure 16C). Interestingly, hepatic Zn 
was significantly decreased (Figure 16B). Similar observations on HDL-C, ALT, and Zn 
were made with another batch of mice (Data not shown). In order to evaluate the effect 
of the dosing of AAV-Cre on liver function, I injected Slc39a8fl/fl mice with AAV-Null [5 
x1011 GC/mouse] and increasing doses of AAV-Cre [0.5, 1.5, 2,5, and 5 x1011 
GC/mouse]. qRT-PCR using primers directed against the deleted exon (exon 3) showed 
that all doses of virus resulted in efficient Slc39a8 deletion in the liver (Figure 16D), while 
primers directed against a region downstream of exon 3 (exon 7) showed a trend of 
increased deletion efficiency as viral dose increased (Figure 16E). 6 weeks after 
injection, HDL-C was progressively decreased as viral dose increased, and 2.5 and 
5*10(11) of virus resulted in significantly decreased HDL-C compared with AAV-Null 
(Figure 16F). Interestingly, hepatic Zn and ApoA-I transcription levels were also 
progressively decreased, while plasma ALT was progressively increased (Figure 16G-I). 
There was a significant positive correlation between HDL-C and hepatic Zn (r=0.4767, 
p=0.0009) (Figure 16J) and a significantly negative correlation between HDL-C and 
plasma ALT (r=-0.4952, p=0.0006) (Figure 16K) in the mice used in these three 
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experiments. Hepatic Zn and plasma ALT were not correlated (Figure 16L). These 
results combined suggest that decreased hepatic Zn and increased ALT may both 
contribute to the decrease of HDL-C in AAV-Cre mice.  It is noteworthy that the decrease 
in HDL-C in AAV-Cre is consistently with the observation in GWAS that decreased 
hepatic SLC39A8 transcription or impaired ZIP8 function is associated with decreased 
HDL-C in human.  
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Figure 16. Acute Slc39a8 liver-specific deletion leads to decreased HDL-C 
contributed by decreased Zn and increased ALT (A) HDL-C of 8-12 weeks old male 
Slc39a8fl/fl mice 2, 4, 6, 8, 11, and 14.5 weeks after injection of AAV-Null or AAV-Cre at a 
dose of 1*10(12). N=4. (B) Hepatic Zn of the week-14.5 time point of (A). N=4. (C) 
Plasma ALT of the week-14.5 time point of (A). N=4. (D-E) qRT-PCR of Slc39a8 in the 
liver of 8-12 weeks old male Slc39a8fl/fl mice 6 weeks after injection with AAV-Null at a 
dose of 5 x1011 GC/mouse or AAV-Cre at a dose of 0.5, 1.5, 2.5, or 5 x1011 GC/mouse 
using primers directed against exon 3 that was deleted in the knockout allele and 
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primers directed against exon 7. N=4. (F) HDL-C of mice from (D-E) 3 and 6 weeks after 
injection of virus. N=4. (G) Hepatic Zn of mice from (D-E) at the week-6 time point. N=4. 
(H) Plasma ALT of mice from (D-E) at the week-6 time point. N=4. (I) Hepatic ApoA-I 
transcription level of mice from (D-E) at the week-6 time point. N=4. All data are shown 
as the mean ± SD. Comparisons between two groups were performed using Studentʼs t-
test. *p≤0.05 compared with the control group. (J-L) Correlations between hepatic Zn 
and HDL-C, plasma ALT and HDL-C, and plasma ALT and hepatic Zn in all AAV-Cre 
mice and controls. Values were normalized to the average of the control group of each 
experiment. Correlation analyses were performed using Pearson test.  
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Genetic liver-specific Slc39a8 deletion combined with a Zn deficient diet leads to 
decreased HDL-C. 
To examine the effect of liver-specific Slc39a8 deletion on HDL-C metabolism in a 
genetic model, Slc39a8fl/fl mice were crossed with Alb-Cre transgenic mice to generate 
Slc39a8 liver-specific knockout (Zip8 LSKO). Zip8 LSKO and heterozygous Zip8 LSKO 
mice did not have a HDL-C phenotype (Figure 17A). This was confirmed by several 
experiments except for one that showed elevated HDL-C in Zip8 LSKO mice on chow 
and western diet (Figure 17B). Given the association of SLC39A8 with BMI, body weight 
of WT an Zip8 LSKO mice were recorded and no difference was observed (Figure 17C).  
 
To bring out a HDL-C phenotype, I challenged Zip8 LSKO mice with a Zn deficient diet 
(ZD), and mice treated with a Zn adequate diet (ZA) were used as control. After 6 weeks 
of dietary treatment, WT/ZD and Zip8 LSKO/ZD mice had significantly decreased plasma 
Zn compared with WT/ZA and Zip8 LSKO/ZA, respectively (WT: -16.5%, p=0.007; Zip8 
LSKO: -18.4%, p=0.022), though there was not difference in plasma Zn between WT/ZD 
and Zip8 LSKO/ZD (Figure 17D). Throughout the treatment, Zip8 LSKO/ZD had the 
lowest HDL-C levels, while HDL-C levels at baseline were virtually the same amongst 
the four groups of mice (Figure 17E), suggesting that Zip8 liver-specific deletion 
combined with ZD resulted in decreased HDL-C. At week 6, Zip8 LSKO/ZD had 
significantly lower HDL-C compared with WT/ZD (-31.1%, p=0.03) and Zip8 LSKO/ZA (-
33.8%, p=0.0002) (Figure 17F), which was further confirmed by FPLC analysis (Figure 
17G). There was no significant difference in hepatic Zn and ApoA-I expression amongst 
the four groups of mice when the mice were sacrificed after 9 weeks of treatment, 
though Zip8 LSKO/ZD had the lowest hepatic Zn levels (Figure 17H and I). These 
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observations suggest that Slc39a8 may act through Zn to regulate HDL-C. The decrease 
of HDL in Zip8 LSKO/ZD is consistent with the observation in GWAS that the minor allele 
of rs13107325 is associated with decreased SLC39A8 in the liver and decreased HDL-C 
in the blood.   
 
 
Figure 17. Genetic liver-specific Slc39a8 deletion combined with a Zn deficient 
diet leads to decreased HDL-C (A) HDL-C of 10-12 weeks old male Slc39a8fl/fl (WT), 
Slc39a8fl/+; Alb-Cre (Zip8 LSKO Het), and Slc39a8fl/fl; Alb-Cre (Zip8 LSKO) mice on chow 
diet. N=7. (B) HDL-C of 10-12 weeks old male WT and Zip8 LSKO mice on chow diet 
followed by western diet for 3 and 6 weeks. N=7. (C) Body weight of mice from (B). N=7. 
(D) Plasma Zn of 10-12 weeks old male WT and Zip8 LSKO mice on Zn adequate (ZA) 
or Zn deficient (ZD) diet for 6 weeks. N=5. (E) Plasma HDL-C of mice from (D) 2, 4, 6, 
and 9 weeks after the diet. N=5. (F) HDL-C of the week-6 time point of (E). N=5. (G) 
Cholesterol levels of fractions of pooled plasma samples from (F) separated by fast 
protein liquid chromatography (FPLC). The peak corresponds to HDL-C fractions. (H) 
Hepatic Zn of mice from (D) at the week-9 time point. N=5. (I) qRT-PCR of ApoA-I in the 
liver of mice from (D) at the week-9 time point. N=5. All data are shown as the mean ± 
SD. Comparisons between two groups were performed using Studentʼs t-test. *p≤0.05.  
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Genetic liver-specific Slc39a8 deletion combined with a Zn deficient diet leads to 
increased glucose tolerance. 
Given the pleiotropic associations of SLC39A8 with metabolic traits and the importance 
of Zn in general metabolism, I examined glucose tolerance of Zip8 LSKO mice on ZD 
diet. Glucose tolerance test demonstrated that Zip8 LSKO/ZD deposed glucose most 
rapidly compared with other three groups of mice (Figure 18A). Area under the curve 
analysis demonstrated that Zip8 LSKO/ZD had significantly lower glucose than WT/ZD (-
23.8%, p=0.021) and Zip8 LSKO/ZA (-29.7%, p=0.0007) (Figure 18B) after glucose 
injection. Glucose transporter type 4 (Glut4) expression was greatly up regulated in the 
inguinal adipose of Zip8 LSKO/ZD (Figure 18C), which may partially explain the faster 
glucose disposal of these mice.  
 
 
Figure 18. Genetic liver-specific Slc39a8 deletion combined with a Zn deficient 
diet leads to increased glucose tolerance (A) Glucose tolerance study of 10-12 
weeks old male Slc39a8fl/fl (WT) and Slc39a8fl/fl; Alb-Cre (Zip8 LSKO) male on Zn 
adequate (ZA) or Zn deficient (ZD) diet for 8 weeks. N=5. (B) Area under the curve of 
(A). (C) qRT-PCR of glucose transporter 4 (Glut4) in the inguinal adipose of mice from 
(A) 9 weeks after the dietary treatment. N=5. All data are shown as the mean ± SD. 
Comparisons between two groups were performed using Studentʼs t-test. *p≤0.05, 
**p≤0.01. 
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Discussion 
Spurred by the observation that genetic variants including a coding variant in the 
SLC39A8 gene are associated with HDL-C, I used Slc39a8 gain-of-function and loss-of-
function mouse models to explore whether and how Slc39a8 regulates HDL-C. I 
discovered that SLC39A8 liver-specific over-expression increased HDL-C, while Slc39a8 
liver-specific deletion decreased HDL-C when deleted acutely with a high dose of AAV or 
in combination with a Zn deficient diet. This study suggests that SLC39A8 may play a 
role in HDL-C regulation and that Zn is involved in this process. The mechanism in which 
Zn may influence HDL-C levels requires further study.  
 
AAV-Cre mediated Slc39a8 liver-specific knockout decreased HDL-C at high doses of 
virus. There is a significant positive correlation between hepatic Zn and HDL-C. 
Furthermore, Albumin-Cre mediated Slc39a8 liver-specific knockout decreased HDL-C in 
combination with a Zn deficient diet. These two observations are consistent with the 
association of rs13107325 (Ala391Thr), the SLC39A8 loss-of-function variant, with lower 
blood HDL-C in human GWAS and the positive correlation between plasma Zn and HDL-
C in human (228). It is worth noting that Zn homeostasis seemed to be very robust in 
Slc39a8 liver-specific knockout mice, as these mice exhibited only moderate and 
transient decrease in hepatic and plasma Zn compared with control, suggesting that 
unlike Mn, other pathways may play greater roles in modulating Zn levels. Zn 
homeostasis is maintained by adjustments in both absorption and excretion (141). Given 
the previous discovery that Zip8 is located on the apical surface of hepatocytes and that 
it mediates re-uptake of Mn from bile, it is likely that Zip8 also functions to reclaim Zn 
from biliary excretion. The primary route of Zn disposal is fecal excretion, which is 
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contributed by Zn from not only biliary secretion, but also pancreatic secretion, 
gastroduodenal secretion, and secretion from other intestinal cell types (232, 233). 
Therefore, hepatic Slc39a8 may have limited influence on the overall Zn homeostasis, 
which may explain the transient and moderate changes of Zn in Slc39a8 liver-specific 
knockout mice. It is also possible that other hepatic Zn transporters are regulated to 
compensate for the deletion of Slc39a8. 
 
Though there is evidence in cell culture and in rats that Zn positively regulates the 
transcription of ApoA-I, I did not observe significant changes in ApoA-I transcription 
levels in Slc39a8 mouse models. It is worth noting that in these experiments, hepatic Zn 
levels were not significantly altered by SLC39A8 liver-specific over-expression or 
Slc39a8 liver-specific deletion when the mice were sacrificed and ApoA-I transcription 
levels were examined. It is possible that Zn and ApoA-I levels were altered at earlier time 
points, which resulted in the HDL-C changes observed.  
 
In summary, this study provides evidence that SLC39A8 may play a role in HDL-C 
regulation and that Zn may be involved in this process. The mechanism in which Zn may 
influence HDL-C requires further study.  
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CHAPTER 5 
 
Slc39a8/Zip8 is essential for ventricular compaction during mouse cardiac 
development  
 
Introduction 
Cardiac ventricular morphogenesis begins from a tubular structure composed of an outer 
one-cell layer of myocardium and an inner one-cell layer of endocardium separated by 
extracellular matrix (ECM), or cardiac jelly (234). Trabeculation in mice begins at 
embryonic day E9.0, when myocardial cells protrude into cardiac jelly to form projections 
lined by endocardium: structures named trabeculae. Trabeculae rapidly grow and 
expand between E9.5 to E13.5. By E14.5, trabeculae are long and thin, with little cardiac 
jelly between myocardium and endocardium. Concomitant with the development of 
coronary circulation, trabeculae collapse into the ventricle wall and become a part of the 
compact myocardium. Therefore, the mature ventricle has thick compact myocardium 
with few trabeculae (235, 236).	  Endocardium plays unique and critical roles in the 
trabeculation and compaction processes by producing signaling molecules that 
orchestrate cardiomyocyte proliferation and differentiation, and enzymes that are 
involved in cardiac jelly production and degradation (234, 237, 238). 
 
Many forms of congenital heart defects are resulted from, or associated with, abnormal 
cardiac trabeculation and compaction. For instance, left ventricle noncompaction (LVNC) 
is a cardiomyopathy caused by arrested compaction. It is characterized by excessive 
trabeculation with deep inter-trabecular recesses and thin compact myocardium (239). It 
usually affects both ventricles, but is more prominent on the left in human. In the 
pediatric population, LVNC is the third most common cardiomyopathy after dilated 
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cardiomyopathy and hypertrophic cardiomyopathy (240). Typical complications of LVNC 
include heart failure, ventricular arrhythmias and systemic embolic events (241). 
Mutations in genes encoding sarcomeric, mitochondrial, cytoskeletal, and nuclear 
membrane proteins and Notch signaling pathway components have been identified in 
LVNC patients (242-246), but the molecular mechanisms remain unresolved in most 
cases, reflecting a lack of understanding of the molecular mechanism underlying the 
compaction process. 
 
Cardiac jelly serves as the media for signal exchanges between endocardium and 
myocardium (247). Perturbation of cardiac jelly production or degradation has been 
shown to cause abnormal trabeculation and compaction. Two major components of 
cardiac jelly are hyaluronan, a mucopolysaccharide, and Versican, a chondroitin sulfate 
proteoglycan. Mice lacking hyaluronan synthase-2 or Versican did not develop 
trabeculae (248-250). On the other hand, a substantial amount of cardiac jelly needs to 
be degraded prior to ventricle compaction. Cardiac jelly degradation is mediated by 
metalloproteinases including Adamts family members. Adamts1 knockout mice 
developed hypertrabeculation and Adamts9 haploinsufficient mice developed ventricle 
noncompaction accompanied by cardiac jelly accumulation (238, 251). Conversely, mice 
over-expressing Adamts1 or Adamts5 exhibited sparse trabeculation due to excessive 
cardiac jelly degradation (238, 252). However, the upstream signaling regulating Adamts 
expression and the mechanism in which cardiac jelly regulates trabeculation and 
compaction is not well understood.  
 
Zinc (Zn) is required for the structure and function of a variety of enzymes and 
transcription factors (128). Zn deficiency has been shown to result in developmental 
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defects including multiple forms of cardiac abnormalities (138, 140). Zn homeostasis is 
primarily regulated by ten Zn exporters and fourteen Zn importers (253). Slc39a8 
(encoding protein Zip8) is one of the cellular Zn importers (63). It has been reported that 
Zip8 promotes cellular Zn uptake to mediate ECM degradation in osteoarthritis (81). 
However, it is not clear whether or how Zn may impact ECM degradation and myocardial 
morphogenesis, and the potential involvement of Slc39a8 in these processes has never 
been addressed.  
 
In this study, I demonstrated that Slc39a8 is crucial for ventricle trabeculation and 
compaction in mouse. Slc39a8 null embryonic hearts exhibited reduced Adamts 
transcription and cardiac jelly degradation. Knocking down SLC39A8 in HUVECs 
resulted in decreased ADAMTS1 transcription by decreasing cellular Zn uptake and 
thereby reducing MTF1 transcriptional activity. Our study revealed a novel regulator of 
ventricle myocardial development and a novel pathway that regulates ECM degradation 
during myocardial morphogenesis. 
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Methods 
Mice. Slc39a8 constitutive knockout allele, C57BL/6-Slc39a8tm1.2 mrl, was generated 
as has been described in Chapter 2. The R26REYFP mice, which have a loxP-flanked 
STOP sequence followed by the Enhanced Yellow Fluorescent Protein gene inserted 
into the Gt(ROSA)26Sor locus, was purchased from the Jackson Laboratory (Stock # 
006148) and crossed with Tie2-Cre transgenic mice (Stock # 004128) or Tnnt2-Cre 
transgenic mice (Stock # 024240) obtained from the Jackson Laboratories. Versican 
heterozygous mice were obtained from Dr Christine B. Kern (Medical University of South 
Carolina). The Versican knockout allele was detected using primers Versican-F: 5ʼ- 
CCATAAAGCCTGTGTGAAATGCC-3ʼ and Versican-R: 5ʼ-	  
CCATAAAGCCTGTGTGAAATGCC-3ʼ.  
 
Cell culture HUVECs (Lonza) were cultured in VascuLife® EnGS medium (Lifeline, Cat. 
No.: LL-0002). To knock down SLC39A8, cells were plated at a density of 2.5x104 per 
well in a 12-well plate and transfected with 10nM Ambion Silencer Select control siRNA 
(Life technologies, Cat. No.: 4390843) or SLC39A8 siRNA (Life technologies, Cat. No.: 
4392420) using RNAiMax (Life Technologies, Cat. No.: 13778075) the next day, when 
they reached 70% confluency. Cells were used for experiment 8 hours after siRNA 
treatment. To chelate Zn, cells were treated with 1uM N,N,N′,N′-Tetrakis(2-
pyridylmethyl)ethylenediamine (TPEN) (Sigma Aldrich, Cat. No.: P4413) for 24 hours. To 
load cells with Zn, cells were treated with ZnCl2 (25 µM) for 4 hours.  
For MTF1 reporter assay (Qiagen, Cat. No.: CCS-5033L) (81), cells were transfected 
with a mixture of a MTF1-responsive firefly luciferase construct and a constitutive renilla 
luciferase construct (40:1) by reverse transfection using Lipofectamine 3000 (Thermo 
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Fisher Scientific, Cat. No.: L3000015). 1x104 cells, 120 ng reporter construct mixture, 
0.12 µl P3000, and 0.2 µl Lipofectamine 3000 were used per well of a 96-well plate. To 
study the effect of SLC39A8 knockdown on MTF1 reporter activity, cells were 
transfected with MTF1 reporter constructs for 24 hours, then treated with 20nM control 
siRNA or SLC39A8 siRNA using RNAiMax for 8 hours before being harvested for the 
reporter assay. To study the effect of Zn chelation, cells were treated with TPEN (1µM) 
24 hours after transfection of the reporter constructs and MTF1 reporter assay was 
performed 24 hours later. To study the effect of Zn overload, cells were treated with 
ZnCl2 (25 µM) 24 hours after transfection of the reporter constructs and MTF1 reporter 
assay was performed 4 hours later. MTF1 reporter assay was performed using Dual-
Luciferase® Reporter Assay System (Promega, Cat. No.: E1910).  
 
Histology, imunostaining, RNA in situ hybridization, and Alcian blue staining. 
Histology, IF staining and Alcian blue staining were performed as was previously 
described (252). Embryos were fixed in 2% paraformaldehyde overnight, dehydrated 
using graded ethanol, and embedded in paraffin. Eight-micrometer thick sections were 
collected. The antibodies used for IF staining were: rat anti-Pecam (1:500, BD 
PharMingen, Cat. No.: 553370), rabbit anti-Versican (1:200, Millipore, Cat. No.: 
AB1033), rabbit anti-DPEAAE (1:200, Pierce, Cat. No.: PA1-1748A), rat anti-BrdU (1:20, 
Accurate Chemical & Scientific Corp, Cat. No.: OBT0030S), and rabbit anti-NICD1 (1:50, 
Cell Signaling, Cat. No.: 4147). Bmp10 in situ hybridization probe was obtained from Dr 
Weinian Shou (Indiana University). Primers used to generate Slc39a8 in situ 
hybridization probe are 5ʼ-	  TGTGACTTGCTATGCCAACC-3ʼ and 5ʼ-	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TCTCCTGCGTACAAGGTGAT-3ʼ. IF images were acquired with a Zeiss LSM 710 
confocal Microscope.  
 
Fluorescence-activated cell sorting (FACS). E12.5 embryos were isolated and kept in 
ice-cold PBS. YFP positive embryos were identified by their YFP epifluorescence. Hearts 
were dissected and digested with Collagenase I (0.5 mg/ml in DMEM basal medium) for 
30 minutes on a shaker at 37 °C and dissociated by pipetting every 5-10 minutes during 
the digestion. Dissociated cells were added into 10 ml DMEM, filtered through a 40 µm 
cell strainer, centrifuged, and re-suspend in sorting buffer (Ca2+/Mg2+ free PBS, 1.5% 
BSA, and 25 mM HEPES). Cells from YFP negative embryos were used to set the YFP 
negative gate, and YFP positive and YFP negative cells from YFP positive embryonic 
hearts were sorted and collected in RLT buffer of the RNeasy Mini kit (Qiagen, Cat. No.: 
74104).  
 
Zn measurements. To measure Zn, mouse embryonic hearts were homogenized in 100 
µl PBS (Ca2+/Mg2+ free) and Zn was measured using an Elan 6100 inductively coupled 
plasma mass spectrometry (ICP-MS) (Perkin Elmer, Shelton, CT) at the PADLS New 
Bolton Center Toxicology Laboratory, School of Veterinary Medicine of the University of 
Pennsylvania, as was previously described (169). Briefly, after weight and volume were 
measured, the sample was digested overnight with twice the amount (weight/volume) of 
70% nitric acid at 70°C and 0.15 ml of the digested sample was diluted with deionized 
water to a final volume of 5 ml for analysis. The concentration was measured using a 
calibration curve of aqueous standards prepared at four different concentrations of Zn. 
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Results were reported in ppm on a weight basis. Total amount of Zn in a heart was 
calculated and normalized to total amount of protein in the heart measured by BCA.   
 
To study cellular Zn uptake, ZnCl2 and 65ZnCl2 (PerkinElmer, Cat. No.: NEZ111) were 
added into HBSS to make the uptake buffer containing 0.1 µM of ZnCl2 and 0.04 µCi/ml 
of radioactivity. Cells were washed with HBSS buffer twice and incubated with the uptake 
buffer at 37°C. 5 minutes later, the uptake buffer was removed and cells were washed 
three times with HBSS buffer. 500 µl 0.1N NaOH was added into each well to digest the 
cells. 2 hours later, 400 µl cell lysate was used for liquid scintillation counting and 50 µl 
cell lysate was used for BCA protein assay. 
 
Microarray and qRT-PCR analysis. Total RNA was isolated using RNeasy mini kit 
(Qiagen, Cat. No.: 74104). Microarray analysis was performed using Affymetrix mouse 
gene 2.0st chips, as was previously described (254). Pathway analysis was performed 
using Gene Ontology. cDNA was synthesized using High Capacity cDNA Reverse 
Transcription Kit (Applied Biosystems, Cat. No.: 4368814). Realtime PCR (qPCR) was 
performed using Fast SYBR Green Mastermix (Life Technologies, Cat. No.: 4385614). A 
list of SYBR primers used can be found in table V. 
 
Western blot. Embryonic mouse hearts were homogenized in 100µl PBS with protease 
and phosphatase inhibitor.15 µg protein was separated via NuPage SDS Page system 
(Invitrogen, Cat. No.: NP0322BOX). Primary antibodies used were anti-NICD1 (1:1000, 
Cell Signaling, Cat. No.: 4147S), anti-DPEAAE (1:2500, Thermo Fisher Scientific, Cat. 
No.: PA1-1748A) and anti-β actin (1:1000, Santa Cruz, Cat. No.: sc-81178). HRP-
100 
conjugated anti-rabbit and anti-mouse secondary antibodies (1:2500, GE Healthcare Life 
Sciences, Cat.No.: NA934V and NA931V) and SuperSignal™ West Femto Maximum 
Sensitivity Substrate (Life Technologies, Cat. No.: 34094) were used to visualize the 
signal. 
 
Statistical analyses. Two-tailed Studentʼs t-test was used to detect differences between 
two groups in all experiments. Chi-square test was performed to compare observed 
genotype distribution of Slc39a8+/- breeding progeny with expected Mendelian ratios. All 
data represent the mean ± SD. p<0.05 was considered to be significant. 
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Table IV. Primers for qPCR analysis in embryonic hearts 
Gene  Sequence 
Slc39a8-forward CAACGCAAAGCCCAGTCTTT 
Slc39a8-reverse GCGTTTGAGAAAAGAGTCCCAA 
Gapdh-forward TGTGTCCGTCGTGGATCTGA 
Gapdh-reverse CCTGCTTCACCACCTTCTTGAT 
Adamts1-forward CTCTCACCCTTCGGAATTTCTG 
Adamts1-reverse GGAGCCACATAAATCCTGTCTG 
Adamts5-forward CGACCCTCAAGAACTTTTGC 
Adamts5-reverse CGTCATGAGAAAGGCCAAGT 
Adamts7-forward TCATGAACATGGTGGCTGGACTCT 
Adamts7-reverse AGTCTCTTCGGCATGGTGTGTGAT 
Adamts15-forward TCTACACCTGACGCCAGATG 
Adamts15-reverse TCACATACCCGGAATAGAAGCA 
Adamts19-forward CCAGATGCCTCCTGCTTTTAC 
Adamts19-reverse GGTGCGGGTGACCTATGAT 
Bmp10-forward ACCAAGCTGAGGACACCGGAAGG 
Bmp10-reverse CTTCGTGGGCACACAGCAGGCTTT 
ADAMTS1-forward CAAAGGCATTGGCTACTTCTTC 
ADAMTS1-reverse TACACACTGTCCTTGCACACAG 
GAPDH-forward GCACCGTCAAGGCTGAGAAC 
GAPDH-reverse TGGTGAAGACGCCAGTGGA 
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Results 
Slc39a8 is expressed in the developing heart and regulates Zn levels.   
qRT-PCR analysis of whole heart demonstrated that Slc39a8 was expressed in the 
developing heart. The expression peaked at E12.5 and then gradually declined to low 
levels in adult hearts (Figure 19A). RNA in situ hybridization analysis confirmed that 
Slc39a8 was expressed in E12.5 heart ventricle (Figure 19B). Further qRT-PCR analysis 
of single cell populations obtained by labeling cells with YFP and isolating them by 
fluorescence-activated cell sorting (FACS) showed that Slc39a8 was expressed in both 
cardiac endothelial cells and myocytes of E12.5 hearts (Figure 19C and D). Slc39a8 
mRNA was efficiently deleted in the Slc39a8-/- hearts (Figure 19E). Consistent with the 
function of Slc39a8 to promote cellular Zn uptake (63), Zn levels were lower in E14.5 
Slc39a8-/- hearts compared to Slc398+/+ hearts (p=0.06) (Figure 19F).  
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Figure 19. Slc39a8 is expressed in the developing heart and regulates Zn levels 
(A) qRT-PCR analysis of Slc39a8 in the whole heart at different developmental stages. 
Gapdh was used as cDNA loading control. n=3 for each time point. (B) RNA in situ 
hybridization showed that Slc39a8 is expressed in the ventricle of E12.5 hearts. Scale 
bars, 250 µm. (C) Slc39a8 is expressed in E12.5 cardiac endothelial cells. 
Fluorescence-activated cell sorting (FACS) showed a clear separation of YFP+ and 
YFP- cell populations of E12.5 Tie2-Cre; R26REYFP/+ hearts. Slc39a8 expression in YFP+ 
and YFP- populations was analyzed by qRT-PCR normalized to Gapdh. n=3 per group. 
(D) Slc39a8 is expressed in E12.5 cardiomyocytes. FACS showed a clear separation of 
YFP+ and YFP- cell populations of E12.5 Tnnt2-Cre; R26REYFP/+ hearts. Slc39a8 
expression in YFP+ and YFP- populations was analyzed by qRT-PCR normalized to 
Gapdh. n=3 per group. (E) qRT-PCR analysis showed that Slc39a8 was efficiently 
deleted in E12.5 Slc39a8-/- hearts. n=3 for each genotype. (F) ICP-MS analysis showed 
Zn was reduced in E14.5 Slc39a8-/- hearts compared to Slc39a8+/+ hearts. Results were 
normalized to protein content. #P=0.06 by Studentʼs t-test. 
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Slc39a8 deletion results in LVNC. 
Slc39a8 +/- mice appeared phenotypically indistinguishable from Slc39a8 +/+ mice. 
Slc39a8 +/- mice were fertile and had normal life span. Genotyping of Slc39a8 +/- breeding 
progeny at different embryonic time points and at weaning revealed that Slc39a8 -/- mice 
were embryonic lethal by E16.5 (Table V). Histological analysis revealed that compared 
to Slc39a8+/+ hearts, Slc39a8-/- hearts exhibited hypertrabeculation and noncompaction 
phenotypes including excessive trabeculae and thin compact myocardium (-54%, 
p<0.001 for E12.5 and -72.7%, p<0.001 for E14.5), which are the hallmarks of LVNC 
(Figure 20A). These phenotypes were evident at E12.5 and became prominent at E14.5. 
Further analysis by both in situ hybridization and qRT-PCR demonstrated that Slc39a8 -/- 
hearts had elevated expression of Bmp10, a cytokine that is an established trabeculae 
marker, and which is known to promote cell proliferation during trabeculation (Figure 20B 
and C) (237). In agreement with this, BrdU immunostaining demonstrated that 
cardiomyocyte proliferation was significantly increased in E12.5 Slc39a8 -/- hearts 
compared to that of Slc39a8+/+ hearts (Figure 20D). Cell death was similar between 
E12.5 Slc39a8+/+ and Slc39a8-/- hearts (Data not shown).  
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Figure 20. Slc39a8 deletion results in LVNC (A) H&E staining showed that Slc39a8-/- 
hearts exhibited hypertrabeculation and noncompaction at E12.5 and E14.5. Arrows 
indicate compact myocardium. The asterisk indicates ventricular septal defect (VSD). (B) 
RNA in situ hybridization demonstrated that Bmp10 transcriptional signal was increased 
in Slc39a8-/- hearts compared to Slc39a8+/+ hearts at E12.5 and E14.5. (C) qRT-PCR 
analysis showed that Bmp10 was significantly increased in E12.5 and E14.5 Slc39a8-/- 
hearts. n=4 for each genotype. (D) IF staining showed that BrdU+ cardiomyocyte 
number was significantly increased in Slc39a8-/- hearts compared to Slc39a8 +/+ hearts at 
E12.5. Embryos were harvested 3 hours after the pregnant mice were intraperitoneally 
injected with BrdU (100 mg/kg body weight). Mf20 marks cardiomyocytes. Ratio of 
BrdU+ cardiomyocytes to total cardiomyocytes per section at similar anatomical levels 
was calculated. n=4 for each genotype. *p<0.05. Scale bars, 250 µm.  
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Table V. Genotype distribution of Slc39a8 progeny (mating: Slc39a8+/- X Slc39a8+/-) 
Stage Total number of 
progeny examined 
Number of Slc39a8-/- 
mice (%) 
p value  
(Chi-square test) 
E12.5 93 20 (21.51%) 0.4709 
E14.5 244 49 (20.08%) 0.07 
E16.5 45 5 (11.11%) 0.0314 
Weaning 104 0 2.4E-9 
p value was calculated using Chi-square test which compares the observed genotype 
distribution and the expected Mendelian ratio (25%). 
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Slc39a8 deletion leads to decreased expression of Adamts metalloproteinases 
and impaired cardiac jelly degradation. 
To understand the potential molecular mechanisms in which Slc39a8 regulates ventricle 
trabeculation and compaction, I performed a microarray analysis with E12.5 Slc39a8+/+ 
and Slc39a8-/- hearts. Interestingly, multiple Adamts metalloproteinases, including 
Adamts 5, 7, 15, and 19, were found to be down-regulated in Slc39a8-/- hearts. These 
findings were further confirmed by qRT-PCR analysis, which showed a 30.5% decrease 
of Adamts1 (p=0.001), 49.7% decrease of Adamts 5 (p<0.001), 30.3% decrease of 
Adamts 7 (p=0.013), 39.8% decrease of Adamts 15 (p=0.003), and 48.3% decrease of 
Adamts 19 (p<0.001) in Slc39a8-/- hearts compared to Slc39a8+/+ hearts (Figure 21A). 
Adamts metalloproteinases are key proteinases that mediate cardiac jelly degradation 
(238, 252). Consistent with this, “proteinaceous extracellular matrix” and 
“metallopeptidase activity” are among the top down-regulated gene categories in 
functional annotations of the microarray data. I therefore examined cardiac jelly by Alcian 
blue staining, which detects major cardiac jelly components including hyaluronan and 
Versican (251, 252). Consistent with decreased expression of Adamts 
metalloproteinases, the intensity of Alcian blue staining was substantially increased in 
E12.5 Slc39a8-/- hearts compared to Slc39a8+/+ hearts (Figure 21B). Furthermore, 
immunostaining demonstrated that Versican was markedly increased, while DPEAAE, a 
cleaved product of Versican by Adamts, was markedly decreased in E12.5 Slc39a8 -/- 
hearts compared to Slc39a8+/+ hearts (Figure 21C). The decrease in DPEAAE was 
further confirmed and quantified by western blot analysis (-39.1%, p=0.001) (Figure 
21C). These observations provided strong evidence that cardiac jelly degradation was 
impaired in Slc39a8-/- hearts.  
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Ectopic cardiac jelly accumulation has been shown to cause hypertrabeculation and 
noncompaction, as was the case of Adamts1 knockout and Adamts9 heterozygous mice. 
The Versican heterozygous mice had decreased Versican compared to wild type mice 
and have been used to rescue the valve anomalies of Adamts5 knockout mice by 
reversing ectopic cardiac jelly accumulation (255). Therefore, I crossed Versican 
heterozygous (Vcan+/-) mice with Slc39a8+/- mice to if Vesican heterozygosity can 
ameliorate the hypertrabeculaion and noncompaction phenotype of Slc39a8-/-. 
Slc39a8+/+; Vcan+/- mice had slightly lower Versican compared to the control Slc39a8+/+; 
Vcan+/+ mice. However, Slc39a8-/-; Vcan+/- mice had substantially higher Versican 
compared to the control (Figure 21D), and the hypertrabeculation and noncompaction 
phenotype was not improved (Data not shown). 
 
Aberrant cardiac jelly accumulation can perturb signal exchanges between endocardium 
and myocardium (238). In agreement with this, immunostaining and western blot 
analysis demonstrated that NICD1, the intracellular domain of Notch receptor 1 and an 
indicator of activated Notch signaling, was significantly increased in E12.5 Slc39a8 -/- 
hearts (Figure 21E), indicating increased Notch signaling activity. Taken together, these 
results demonstrated that Slc39a8 deletion resulted in aberrant cardiac jelly 
accumulation due to impaired degradation as a result of decreased expression of 
Adamts metalloproteinases.  
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Figure 21. Slc39a8 deletion leads to decreased expression of Adamts 
metalloproteinases and impaired cardiac jelly degradation. (A) qRT-PCR analysis 
showed decreased expression of Adamts metalloproteinases in Slc39a8-/- hearts at 
E12.5. n=3 for each genotype. **p<0.01. (B) Alcian blue staining showed that cardiac 
jelly was substantially increased in Slc39a8-/- hearts compared to Slc39a8+/+ hearts at 
E12.5. Scale bars, 50 µm. (C) Immunostaining demonstrated that Versican was greatly 
increased in Slc39a8-/- hearts, whereas DPEAAE was markedly reduced in Slc39a8-/- 
hearts compare to Slc39a8+/+ hearts at E12.5. Scale bars, 200 µm. Western blot (WB) of 
DPEAAE on E12.5 Slc39a8+/+ and Slc39a8-/- hearts is shown on the right. n=4 for each 
genotype. β-actin was used as protein loading control. The densitometry analysis is 
shown at in the right bottom panel. ***p< 0.001. (D) Immunostaining demonstrated that 
immunoreactive signal of Versican in the heart ventricle of Slc39a8+/+; Vcan+/- is weaker 
than control, but that of Slc39a8-/-; Vcan+/- is much stronger than control at E12.5. Scale 
bars, 50 µm. (E) Immunostaining demonstrated that immunoreactive signal of NICD is 
greater in the heart ventricle of Slc39a8-/- compare to Slc39a8+/+. Scale bars, 50 µm. WB 
of NICD on E12.5 Slc39a8+/+ and Slc39a8-/- hearts is shown on the right. n=3 for each 
genotype. β-actin was used as protein loading control. The densitometry analysis is 
shown in the right bottom panel. **p< 0.01. 
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Endothelial-specific Slc39a8 deletion recapitulates phenotypes of the global 
deletion. 
Given that Slc39a8 is present in endocardial cells and that Adamts metalloproteinases 
are primary expressed in endocardial cells, I generated endothelial-specific Slc39a8 
knockout mice by crossing Slc39a8fl/fl with Tie2-Cre transgenic mice. Slc39a8fl/fl; Tie2-Cre 
mice recapitulated the hypertrabeculation and noncompaction phenotypes of Slc39a8-/- 
and LVNC patients (Figure 22 A). In situ hybridization showed that the trabeculae marker 
Bmp10 was also elevated in Slc39a8fl/fl; Tie2-Cre embryonic hearts compared with 
Slc39a8fl/fl, confirming the hypertrabeculation phenotype (Figure 22B). Furthermore, 
E12.5 Slc39a8fl/fl; Tie2-Cre hearts displayed increased Versican, decreased DPEAAE, 
and increased NICD shown by immunostaining (Figure 22C and D), indicating that 
endothelial-specific Slc39a8 deletion leads to impaired cardiac jelly degradation and 
ectopic Notch signaling activity, as has been observed in E12.5 Slc39a8-/- hearts. 
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 Figure 22. Endothelial-specific Slc39a8 deletion recapitulates phenotypes of the 
global deletion. (A) H&E staining showed that Slc39a8fl/fl; Tie2-Cre hearts exhibited 
hypertrabeculation and noncompaction at E14.5. Scale bar, 250 μm. (B) RNA in situ 
hybridization demonstrated that Bmp10 transcription was increased in Slc39a8fl/fl; Tie2-
Cre hearts compared to Slc39a8fl/fl hearts at E12.5 and E14.5. Scale bar, 250 μm. (C) 
Immunostaining demonstrated that immunoreactive signal of Versican was greatly 
increased in Slc39a8fl/fl; Tie2-Cre hearts, whereas DPEAAE was markedly reduced in 
Slc39a8fl/fl; Tie2-Cre hearts compare to Slc39a8fl/fl hearts at E12.5. Scale bars, 200 μm. 
(D) IF staining showed increased NICD1 in E12.5 Slc39a8fl/fl; Tie2-Cre hearts compared 
to Slc39a8fl/fl hearts. Scale bar, 250 μm.  
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SLC39A8 knockdown in HUVECs results in decreased ADAMTS1 expression and 
MTF1 transcriptional activity. 
To further explore the potential molecular mechanism in which Slc39a8 regulates 
Adamts expression, I knocked down SLC39A8 in human umbilical vein endothelial cells 
(HUVECs) using siRNA. Western blot analysis confirmed effective knockdown of 
SLC39A8 (Figure 23A). Consistent with decreased Adamts in embryonic Slc39a8-/- 
hearts, SLC39A8 knockdown resulted in decreased ADAMTS1 expression in HUVECs (-
48.6%, p<0.001) (Figure 23C). It has been reported that Slc39a8 regulates Adamts 
expression by modulating cellular Zn uptake and subsequently MTF1 transcriptional 
activity during osteoarthritis. Consistent with this model and the in vivo observation of 
reduced Zn in Slc39a8-/- embryonic hearts, SLC39A8 knockdown led to reduced cellular 
Zn uptake (-38.0%, p=0.0002) (Figure 23B). To test whether reduced Zn influx 
contributes to the reduction of ADAMTS1 expression by SLC39A8 knockdown, we 
treated HUVECs with TPEN, a Zn-specific metal ion chelator (256). Interestingly, TPEN 
treatment also resulted in reduced ADAMTS1 expression (-28.3%, p=0.009). 
Conversely, ZnCl2 treatment increased ADAMTS1 expression (+43.0%, p=0.003) (Figure 
22C). Lastly, we sought to understand whether SLC39A8 regulates the expression of 
ADAMTS1 through modulating MTF1 transcriptional activity by Zn influx. We examined 
MTF1 transcriptional activity using a MTF1-responsive luciferase construct which 
encodes the firefly luciferase reporter gene under the control of MTF1 transcriptional 
response element (256) (Figure 23D). Both SLC39A8 knockdown and TPEN treatment 
resulted in significantly decreased MTF1 transcriptional activity (-39.0%, p=0.05 and -
74.3%, p=0.001), while ZnCl2 treatment greatly enhanced MTF1 transcriptional activity 
(4.37 fold, p=0.05) (Figure 23E). Taken together, these results strongly suggest that 
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SLC39A8 regulates ADAMTS1 expression by modulating cellular Zn uptake and 
subsequently MTF1 transcriptional activity. 
 
Figure 23. SLC39A8 knockdown in HUVECs results in decreased ADAMTS1 
expression and MTF1 transcriptional activity (A) Western blot and densitometry 
analysis showed that SLC39A8 siRNA treatment resulted in efficient SLC39A8 
knockdown in HUVECs. HUVECs were treated with SLC39A8 siRNAs or control 
scramble siRNAs for 24 hours. n=4 for each condition. ***p<0.001. (B) 65Zn uptake was 
significantly reduced in SLC39A8 siRNA treated HUVECs compared to that in control 
siRNA treated cells. N=4 for each group. ***p<0.001. (C) qRT-PCR analysis of 
ADAMTS1 expression in HUVECs treated with SLC39A8 siRNA, TPEN or ZnCl2. 
ADAMTS1 expression was significantly decreased in SLC39A8 siRNA or TPEN-treated 
HUVECs, but increased in ZnCl2-treated HUVECs. n=4 for each condition. **p<0.01; 
***p<0.001. (D) A schematic presentation of MTF1 reporter assay is shown on the left. 
TRE: tandem response element. MTF1 transcriptional activities were significantly 
decreased in HUVECs treated with SLC39A8 siRNA or TPEN but significantly increased 
in HUVECs treated with ZnCl2 compared to the corresponding controls (n=8, n=6, and 
n=4 respectively). Luciferase activities of firefly were normalized by renilla. MTF1 
reporter activities in each treatment condition were normalized to the average of the 
corresponding control groups. *p< 0.05, **p< 0.01.  
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Discussion 
Ventricle noncompaction is a cardiomyopathy that can develop severe complications 
over time. Excessive cardiac jelly degradation leads to hypotrabeculation while impaired 
cardiac jelly degradation results in hypertrabeculation and noncompaction. However, it is 
not well understood how cardiac jelly degradation is regulated as myocardial 
morphogenesis progresses. In this study, we demonstrated that Slc39a8-/- mice 
developed ventricle hypertrabeculation and noncompaction and impaired cardiac jelly 
degradation as a result of decreased Adamts metalloproteinase expression. 
Consistently, knocking down SLC39A8 in HUVECs decreased ADAMTS1 expression by 
reducing cellular Zn uptake and MTF1 transcriptional activity.  
 
Slc39a8 hypomorphic mice have been reported to exhibit diminished Zn and Fe, 
multiple-organ hypoplasia, anemia and perinatal death, although it was not reported 
whether there were cardiac defects in those mice (82). There were quite a few 
similarities in phenotypes between our Slc39a8 -/- mice and the Slc39a8 hypomorphic 
mice, such as early embryonic/neonatal lethality and reduced cellular Zn uptake. 
However, it does appear that the phenotypes of Slc39a8-/- mice are more severe than 
those of the Slc39a8 hypomorphic mice, which is likely a reflection of the difference in 
the degree of the loss of gene function in these two different lines of mice. 
 
One key finding of our study is that deletion of Slc39a8, a Zn transporter, in mice leads 
to ventricle noncompaction. LVNC is classified by American Heart Association as a 
primary genetic cardiomyopathy (257).	  Familial occurrence is frequent, and autosomal 
dominant, autosomal recessive, X-linked, and maternal transmissions have been 
observed (258). Multiple genetic mutations have been identified in LVNC patients, but 
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the molecular mechanisms underlying LVNC remain elusive (258). Our study supports 
the notion that LVNC is a distinct genetic cardiomyopathy with a developmental basis. It 
establishes the causal relationship between Slc39a8 loss-of-function and LVNC in 
mouse and provides insight into the mechanism underlying the disease. Our study 
suggests that SLC39A8 might be considered as a candidate gene when screening 
LVNC patients for gene mutations, and that Zn deficiency may be involved in the 
pathogenesis of LVNC. This is in agreement with previously studies showing that 
maternal Zn deficiency resulted in multiple forms of cardiac abnormalities including thin 
ventricular wall and irregular trabeculae, and suggests that genetic testing for SLC39A8 
mutations may be of potential pathogenetic and therapeutic implications (138, 140). 
 
Another key finding of our study is the regulation of Adamts metalloproteinases and the 
subsequent cardiac jelly degradation by the Zn-Slc39a8-Mtf1 axis during heart ventricle 
trabeculation and compaction. It is known that Adamts metalloproteinases are repressed 
at the initial stage of trabeculation when cardiac jelly is required (238, 252). However, it 
is unknown how they are de-repressed at the end of the trabeculation stage to degrade 
cardiac jelly and to terminate trabeculation. The Zn-Slc39a8-Mtf1 axis has been reported 
in chondrocytes to upregulate matrix degrading enzymes including Adamts5 during 
osteoarthritis (81). We demonstrated that this regulation is conserved in endothelial cells 
and that it plays a novel and important role in the regulation of Adamts expression, 
cardiac jelly degradation, and myocardial morphogenesis. An interesting observation is 
that Slc39a8 expression peaked at E12.5, which matched very well with the initiation of 
Adamts1 de-repression and cardiac jelly degradation and the termination of 
trabeculation (238). 
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Tie2-Cre results in endocardial gene deletion at E9.0 or earlier (238), which is before the 
onset of the phenotype and the rise of Slc39a8 expression in the whole heart. Slc39a8fl/fl; 
Tie2-Cre recapitulated the phenotypes of Slc39a8-/- mice, including hypertrabeculation, 
noncompaction, impaired cardiac jelly degradation, and ectopic Notch signaling activity. 
These observations provide strong evidence that the regulation of Adamts by Slc39a8 is 
local to endocardial cells. It is worth noting that Tie2 promoter also drives Cre expression 
in endothelial cells and hematopoietic cells (259). Therefore, it can not be ruled out 
completely that these two cell types may contribute to the phenotypes of the global 
knockout mice. 
 
Various mouse models with cardiac jelly defects have established the role of cardiac jelly 
in trabeculation and compaction. Though the mechanism is not completely understood, 
one hypothesis is that cardiac jelly defects can disrupt signaling transduction between 
the endocardium and the myocardium. Our observation of elevated Notch signaling and 
Bmp10 in Slc39a8-/- heart provided support for this hypothesis. Further studies are 
required to elucidate the mechanism underlying the interaction between cardiac jelly and 
signaling transduction and the impact it has on myocardial morphogenesis. 
 
Collectively, this study reveals a novel gene underling ventricle noncompaction and a 
novel regulatory pathway mediating ECM degradation during myocardial morphogenesis 
(Figure 24). It suggests that Slc39a8 may be screened for mutations in patients with 
ventricle noncompaction and other diseases involving dysregulation of ECM 
degradation.  
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Figure 24. Slc39a8/Zip8 influences ECM degradation by mediating cellular Zn 
uptake Endocardial Zip8 mediates cellular uptake of Zn, which binds to metal-regulatory 
transcription factor 1 (Mtf1) and promotes the transcription of Adamts 
metalloproteinases. Adamts metalloproteinases mediates cardiac jelly degradation, 
which is required for ventricle compaction. In the absence of Zip8, cellular Zn uptake is 
blocked, Mtf1 transcriptional activity is suppressed, and Adamts metalloproteinase 
transcription is reduced, leading to ectopic cardiac jelly accumulation and ventricle 
noncompaction.  
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CHAPTER 6 
	  
Discussion 
Genome-wide association studies have identified genomic regions that are associated 
with common complex traits and diseases. These regions harbor genes that may be 
novel regulators of health and disease. Validating the effects of these genes and 
elucidating the mechanism will provide important insight into biology and invaluable 
targets for drug discovery. A good example is the SORT1 locus, which was found to be 
strongly associated with both plasma LDL-C and myocardial infarction in humans by 
GWAS. Functional studies demonstrated that a common non-coding SNP in this locus 
created a transcription factor-binding site, which in turn altered the expression of the 
SORT1 gene. Furthermore, manipulating the expression of Sortilin in mice altered 
plasma LDL-C and very low-density lipoprotein (VLDL) (260). These observations 
combined demonstrated that SNPs identified by GWAS can directly contribute to clinical 
phenotypes and that the GWAS approach has the potential of identifying novel 
therapeutic targets. 
 
One challenge facing the GWAS approach is the identification of the causal SNP and 
causal gene of a genomic locus. For a SNP that falls in the coding region, in silico tools 
can be employed to predict whether it affects the function of the protein, which can 
further be validated using in vitro or in vivo functional assays. However, the majority of 
the GWAS-identified SNPs fall in non-coding regions whose function is less well 
annotated. To test whether a non-coding SNP is causal, multiple possibilities need to be 
considered, such transcriptional regulation, non-coding RNA function, and epigenetic 
regulation (261). Identification of the causal gene can also be challenging for the same 
reason that most of the SNPs are non-coding. One way to shed light upon the causal 
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gene is expression quantitative trait loci (eQTL) analysis, which examines the 
association of a SNP with the expression level of a gene. If the expression of a gene is 
associated with a SNP, it is likely that the gene is regulated by the SNP, which in turn 
has an effect on the trait (262). In the case of the SLC39A8 locus, the lead SNP in all of 
the GWAS is a coding variant rs13107325 (Ala391Thr). There is no SNP within the 
flanking 500 kb that is in high linkage disequilibrium (r>0.8) with rs13107325 
(Ala391Thr). Rs13107325 (Ala391Thr) was predicted in silico to be deleterious to ZIP8 
function, and has been shown experimentally to impair Cd and Zn transport by ZIP8. In 
addition, it is an eQTL for SLC39A8 in the liver, and the minor allele is associated with 
decreased SLC39A8. These observations combined strongly suggest that rs13107325 
(Ala391Thr) is the causal SNP and that SLC39A8 is the causal gene of this locus. 
Furthermore, they provide important information as to the directionality in which 
SLC39A8 may be regulating the GWAS traits, which is that decreased SLC39A8 
expression or reduced ZIP8 function may lead to decreased whole blood Mn, decreased 
blood pressure, decreased HDL-C, increased BMI, and increased risk of schizophrenia.  
 
Genetically modified mouse models enable functional studies of a gene in a living 
mammalian system, and have been widely used for validation once a potential causal 
gene is identified by GWAS. In addition, mouse models are also instrumental in 
modeling genetic diseases. Slc39a8 loss-of-function mouse models recapitulated 
several traits of SLC39A8 loss-of-function human, including decreased Mn (rs13107325 
minor allele carriers and patients with SLC39A8 mutations), impaired protein N-
glycosylation (rs13107325 minor allele homozygotes and patients with SLC39A8 
mutations), and decreased blood pressure (rs13107325 minor allele carriers), validating 
the effect of SLC39A8 on whole blood Mn and blood pressure. Furthermore, rs13107325 
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minor allele homozygotes recapitulated the increase of NOx observed in Slc39a8 loss-
of-function mice, which strongly suggest that NO may be the underlying mechanism in 
which SLC39A8 regulates blood pressure in human. Correlations between plasma Mn, 
arginase, and NO have been observed in human (263, 264). It will be interesting to see 
whether rs13107325 minor allele homozygotes have decreased arginase activity in the 
plasma.  
 
It is worth noting that there are limitations in the use of mice to model human traits and 
diseases. For instance, liver-specific over-expression of SLC39A8 induced a transient 
increase in HDL-C, while genetic Slc39a8 liver-specific knockout mice did not develop a 
HDL-C phenotype on chow die. One explanation for this lack of HDL-C phenotype in 
mice may be the difference in Zn regulation between mouse and human, such as 
differential expression levels of SLC39A8 and other Zn transporters in the liver, as well 
as differential Zn absorption and excretion machinery. Another explanation may be the 
difference in HDL regulation between mouse and human. For instance, CDG patients 
with β-1, 4-galactosyltransferase mutations have been found to have strongly increased 
HDL-C, aberrantly glycosylated cholesterylester transfer protein (CETP), and decreased 
CETP activity (201). If SLC39A8 regulates HDL-C by modulating CETP glycosylation 
and activity in human, Slc39a8 mouse models will not be able to recapitulate the 
phenotype since mice do not express CETP. It will be interesting to examine HDL-C in 
Slc39a8 mouse models injected with AAV-CETP. 
 
My study provides insight into the possible mechanism underlying the association of 
SLC39A8 with schizophrenia and BMI. It has been shown that schizophrenia patients 
had down-regulated glycosyltranferases in the prefrontal cortex, altered N-glycome in 
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the cerebrospinal fluid and serum, and abnormal N-glycosylation of several 
neurotransmitter receptors (265-269). It is possible that N-glycosylation defects may play 
an etiologic role in the pathogenesis of schizophrenia, and that it is related to the 
association of SLC39A8 with schizophrenia. In terms of BMI, studies that examined the 
correlation between plasma Zn levels and obesity have generated mixed results (270, 
271), and very little study has been done to examine the correlation between Mn and 
obesity. Both Zn and Mn have been shown to be required for insulin secretion (272, 
273). It is possible that SLC39A8 affects body weight through glycemic traits. Further 
studies are required to better understand the potential role of SLC39A8 in the 
pathogenesis of schizophrenia and obesity.  
 
The study of the role of Zip8 during embryonic development in mouse identified Zip8 as 
a novel regulator of heart ventricle compaction and the Zn-Zip8-Mtf1 axis as a novel 
regulatory pathway of Adamts metalloproteinase expression and ECM degradation 
during myocardial morphogenesis. In addition, it establishes Slc39a8-/- as a new mouse 
model of left ventricle noncompaction (LVNC), a genetic disorder with elusive etiology. 
Studies in mice have revealed a correlation between ECM accumulation and 
trabeculation, which is in agreement with my observation in Slc39a8-/- mice. To prove that 
ectopic ECM accumulation is causal to the hypertrabeculation and noncompaction 
phenotype of Slc39a8-/- mouse hearts, I attempted to rescue the phenotype by crossing 
Slc39a8-/- with Versican+/-. However, Versican heterozygosity resulted in only a small 
decrease of Versican, and the phenotype was not rescued. Conditional Versican mouse 
model has been generated (274). It will be interesting to make Versicanfl/fl; Slc39a8fl/fl; 
Tie-Cre/ERT2 mice and see whether induced complete Versican deletion at E12.5 or 
earlier will be able to rescue the phenotype. Notch signaling activity is increased in 
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Slc39a8fl/fl hearts. Though it is generally believed that ECM can affect signaling 
transduction, the interaction between ECM and signaling transduction during cardiac 
morphogenesis has not been carefully examined to date. One way to interrogate this 
question is to examine Notch signaling activity in the heart of Versicanfl/fl; Slc39a8fl/fl; Tie-
Cre/ERT2 mice to see if reduction of Versican will in turn reduce Notch signaling activity. 
Dysregulation of Notch signaling activity has been implicated in LVNC in mouse and 
human (246, 275). It is possible that elevated Notch signaling is mediating the effect of 
ECM accumulation on compaction in Slc39a8fl/fl hearts. To prove this, a rescue 
experiment that inhibits Notch signaling activity is required.  
 
The role of SLC39A8 in development has been firmly established by the Slc39a8 
hypomorph mouse model, my Slc39a8-/- mouse model, and by SLC39A8-CDG patients. 
The main phenotype reported in the Slc39a8 hypomorph mouse model is anemia 
potential due to Fe deficiency, and the main phenotype reported in the patients is 
neurological and skeletal abnormalities due to Mn deficiency, while I observed a LVNC 
phenotype in the heart due to Zn deficiency. The reason for these different observations 
in different models may have to do with species and degrees of loss of gene function. It 
is also possible that the phenotype observed in one study has simply not been examined 
sufficiently in others. It is worth examining the neurological and skeletal phenotypes of 
Slc39a8-/- mice to see if they can be used as a mouse model of SLC39A8-CDG. It will 
also be interesting to examine to cardiac phenotype of SLC39A8 patients. 
 
SLC39A8-CDG is an autosomal recessive trait, indicating that one functional allele of 
SLC39A8 is sufficient to permit normal development. This is in agreement with my 
observation that Slc39a8+/- embryos are superficially indistinguishable from Slc39a8+/+, 
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despite 50% decrease of Slc39a8 expression. Adult Slc39a8+/- and Slc39a8fl/+; Alb-Cre 
mice had around 50% deletion of Slc39a8 and around 30% decrease in arginase activity 
in the liver compared with 90% of Slc39a8 deletion and 70% decrease in arginase 
activity in Zip8 LSKO and iKO. The NOx, blood pressure and glycosylation phenotypes 
were not examined in Slc39a8+/- or Slc39a8fl/+; Alb-Cre mice and heterozygous 
rs13107325 minor allele carriers. It will be interesting to see if the heterozygous minor 
allele carriers have intermediate NOx levels in the plasma, since eQTL studies have 
shown that they have intermediate Slc39a8 level in the liver. 
 
My thesis illustrates that when interrogating the mechanism underlying the association 
between a novel gene and complex traits, it is important to have a good and 
comprehensive understanding of the known function of the gene and the regulatory 
machinery of the trait. In the case of SLC39A8, in adult human and mice, it mediates the 
reuptake of Mn into hepatocytes to regulate whole-body Mn homeostasis and eventually 
influence complex traits via Mn-dependent enzymes. In mouse embryos, it mediates 
uptake of Zn into endocardial cells to modulate transcriptional activity of a Zn-sensing 
transcription factor, which in turn influences ECM degradation and cardiac development. 
Though in adult mice, Slc39a8 does not seem to be essentially for Zn metabolism, it can 
not be ruled out that it regulates Zn metabolism in adult human, or that it mediates Zn 
transport in specific cell types. Making connections between the known function of a 
gene and regulatory machinery of a trait, in the meantime taking into account stage 
(adult vs. development), species (human vs. mouse), level of examination (cell types, 
organ, or whole body), and many other factors, will facilitate the formation of plausible 
hypotheses for testing and eventually lead to successfully target validation. 
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In summary, my dissertation revealed the mechanism underlying the association of 
SLC39A8 with whole blood Mn and blood pressure and provided insight into its 
association with other traits including HDL-C, BMI, and schizophrenia. In addition, it 
identified SLC39A8 as a novel gene underlying LVNC and the Zn-Zip8-Mtf1 axis as a 
novel regulatory pathway of ECM degradation during myocardial morphogenesis in 
mouse. It highlights the pleiotropic physiological and pathological effects of essential 
trace metal ions Mn and Zn and the complexity of their metabolism. It serves as a great 
example where human genetic studies lead to laboratory findings that are of clinical 
relevance and mouse models prove instrumental in revealing the mechanism underlying 
complex traits in human.   
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